vishay_def14a.htm
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED
IN PROXY STATEMENT
SCHEDULE 14A
INFORMATION
Proxy Statement
Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment
No. )
Filed by the Registrant
[x]
Filed by a Party other
than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy
Statement
[_] Soliciting Material Under
Rule
[_] Confidential,
For Use of
the
14a-12
Commission Only (as permitted
by Rule 14a-6(e)(2))
[x] Definitive Proxy Statement
[_] Definitive
Additional Materials
Vishay Intertechnology,
Inc.
------------------------------------------------------------------------------------------------------------------------------------------------------
(Name of Registrant as
Specified In Its Charter)
------------------------------------------------------------------------------------------------------------------------------------------------------
(Name of Person(s)
Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee
(Check the appropriate box):
[x] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
1) Title of
each class of securities to which transaction applies:
____________________________________________________________________________________
2) Aggregate number of securities to
which transaction applies:
3) Per unit price or
other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the
amount on
which the filing fee is
calculated and state how it was
determined):
4) Proposed maximum aggregate value of
transaction:
____________________________________________________________________________________
5) Total fee paid:
[_] Fee paid previously with preliminary
materials:
[_] Check box if any part of the fee is offset
as provided by Exchange Act Rule
0-11(a)(2) and identify the
filing for which
the offsetting fee was paid
previously. Identify the previous
filing by registration statement number,
or the form
or
schedule and the date of its
filing.
____________________________________________________________________________________
1) Amount
previously paid:
____________________________________________________________________________________
2) Form,
Schedule or Registration Statement No.:
____________________________________________________________________________________
3) Filing
Party:
____________________________________________________________________________________
4) Date
Filed:
VISHAY INTERTECHNOLOGY, INC.
63 LANCASTER
AVENUE
MALVERN, PENNSYLVANIA 19355
April 27,
2010
Dear Stockholder:
You are cordially
invited to attend the 2010 Annual Meeting of Stockholders of Vishay
Intertechnology, Inc., to be held at 10:30 a.m., local time, on Wednesday, June
16, 2010, at The Rittenhouse Hotel Ballroom, 2nd Floor at 210 West
Rittenhouse Square, Philadelphia, PA 19103. The Board of Directors looks forward
to greeting you personally at the annual meeting.
During the annual
meeting, we will discuss each item of business described in the attached Notice
of Annual Meeting of Stockholders and proxy statement and provide a report on
Vishay’s business operations. There will also be time for questions.
On behalf of the
Board of Directors, I would like to express our appreciation for your continued
interest in the affairs of Vishay. We hope you will be able to attend the annual
meeting. Whether or not you expect to attend the annual meeting, and regardless
of the number of shares you own, it is important to us and to our business that
your shares are represented and voted at the annual meeting. Therefore, you are
encouraged to sign, date, and return the enclosed proxy card in the return
envelope provided so that your shares will be represented and voted at the
annual meeting.
Sincerely,
|
|
|
|
Dr. Felix Zandman
|
Executive Chairman of the Board of
Directors |
Important Notice Regarding the Availability of
Proxy Materials for the
Annual Meeting of Stockholders to be Held June 16,
2010.
The following materials, also included with
this Notice, are available for view on
the Internet:
Proxy Statement for the 2010 Annual Meeting of
Stockholders
2009 Annual Report to
Stockholders
To view these materials, visit
ir.vishay.com.
VISHAY INTERTECHNOLOGY, INC.
63 LANCASTER
AVENUE
MALVERN, PENNSYLVANIA 19355
NOTICE OF 2010 ANNUAL MEETING OF
STOCKHOLDERS
TO BE HELD ON TUESDAY, June 16, 2010
The 2010 Annual
Meeting of Stockholders of Vishay Intertechnology, Inc. will be held at The
Rittenhouse Hotel Ballroom, 2nd Floor at 210 West
Rittenhouse Square, Philadelphia, PA 19103, on Wednesday, June 16, 2010 at 10:30
a.m., local time. The meeting will be held to consider and act upon:
|
1. |
|
the election of
three directors to hold office until 2013; |
|
|
|
2. |
|
the ratification
of our independent registered public accounting firm; |
|
|
|
3. |
|
if properly
presented at the meeting, a stockholder proposal described in the Proxy
Statement; and |
|
|
|
4. |
|
such other
business as may be brought properly before the
meeting. |
The stockholders of
record at the close of business on April 19, 2010 will be entitled to vote at
the annual meeting or at any adjournment thereof. Whether or not you expect to
attend the meeting in person, please complete, date, and sign the enclosed proxy
card and return it without delay in the enclosed envelope which requires no
additional postage if mailed in the United States.
If you are enrolled
in our electronic proxy materials delivery service and received these proxy
materials via the Internet, you will need to follow the procedures for online
voting to vote your shares.
By
Order of the Board of Directors, |
|
|
Peter
G. Henrici |
Corporate
Secretary |
Malvern,
Pennsylvania
April 27, 2010
TABLE OF CONTENTS
SECTION |
|
|
|
|
About the Meeting |
1 |
|
|
Governance of the Company |
5 |
|
|
Director Compensation |
10 |
|
|
Proposal One – Election of
Directors |
11 |
|
|
Report of the Audit Committee |
14 |
|
|
Proposal Two – Ratification of
Appointment of Independent Registered Public Accounting
Firm |
15 |
|
|
Stockholder Proposal |
16 |
|
|
Security Ownership of Certain Beneficial
Owners and Management |
18 |
|
|
Executive Compensation |
20 |
|
|
Report of the Compensation
Committee |
31 |
|
|
Compensation Tables |
32 |
|
|
Certain Relationships and Related
Transactions |
48 |
|
|
Other Matters |
49 |
|
|
Availability of Annual Report and Form
10-K to Stockholders |
49 |
|
|
Stockholder Proposals for 2010 Annual
Meeting |
49 |
VISHAY INTERTECHNOLOGY, INC.
63 LANCASTER
AVENUE
MALVERN, PENNSYLVANIA 19355
________________
PROXY
STATEMENT
________________
The accompanying
proxy is solicited by the Board of Directors of Vishay Intertechnology, Inc. for
use at the 2010 Annual Meeting of Stockholders of Vishay to be held at The
Rittenhouse Hotel Ballroom, 2nd Floor at 210 West
Rittenhouse Square, Philadelphia, PA 19103 on Wednesday, June 16, 2010 at 10:30
a.m., local time, or any adjournments thereof.
We are first sending
the proxy materials to stockholders on or about April 27, 2010.
ABOUT THE MEETING
Why did I receive these materials?
We hold a meeting of
stockholders annually. This year’s meeting will be held on June 16, 2010. There
will be several items of business that must be voted on by our stockholders at
the meeting, and our Board of Directors is seeking your proxy to vote on these
items. This proxy statement contains important information about Vishay
Intertechnology, Inc. and the matters that will be voted on at the meeting.
Please read these materials carefully so that you have the information you need
to make informed decisions. Throughout this proxy statement, we will refer to
ourselves as “Vishay Intertechnology, Inc.,” “Vishay,” “we,” “our,” or the
“Company.”
What is a proxy?
A proxy is your legal
designation of another person to vote the shares of stock that you own. The
person you designate to vote your shares is also called a proxy. When you submit
a proxy, the people named on the proxy card are required to vote your shares at
the annual meeting in the manner you have instructed.
What is the record date and why is it important?
The record date is
the date used by our Board of Directors to determine which stockholders are
entitled to receive notice of, and vote on the items presented at, the annual
meeting. Our Board established April 19, 2010 as the record date for the 2010
annual meeting.
What is the difference between “Stockholders of Record” and “Beneficial
Owners”?
If your shares are
registered directly in your name with Vishay’s transfer agent, you are
considered, with respect to those shares, the stockholder of record. The proxy
statement, annual report and proxy card have been sent directly to you by
Vishay.
If your shares are
held in a stock brokerage account or by a bank or other nominee, you are
considered the beneficial owner of shares held in street name. This proxy
statement and annual report have been forwarded to you by your broker, bank, or
nominee who is considered, with respect to those shares, the stockholder of
record. As the beneficial owner, you have the right to direct your broker, bank,
or nominee how to vote your shares by using the voting instruction card included
in the mailing or by following their instructions for voting.
Who can attend the meeting?
All stockholders as
of the record date, or their duly appointed proxies, are invited to attend the
meeting.
1
What proposals will I be voting on and how does the Board of Directors
recommend I vote?
The Board of
Directors’ recommendations are set forth together with the description of each
proposal in this proxy statement. In summary, the Board of Directors (the
“Board”) recommends a vote
- FOR the election of three directors to hold
office for terms of three years and until their successors are duly elected
and qualified (see Proposal One); and
- FOR the ratification of the appointment of
Ernst & Young LLP as Vishay’s independent registered public accounting
firm for the year ending December 31, 2010 (see Proposal
Two).
- AGAINST the stockholder proposal asking that our
stockholders urge the Board to arrange for the sale of Vishay Intertechnology,
Inc. to the highest bidder (see the Stockholder Proposal).
Does Vishay have more than one class of stock outstanding?
We have two classes
of stock outstanding, common stock and Class B common stock. On the record date,
there were 172,288,582 shares of common stock and 14,352,839 shares of Class B
common stock outstanding and entitled to vote.
What are the voting rights of each class of stock?
Each share of common
stock will be entitled to one vote and each share of Class B common stock will
be entitled to 10 votes with respect to each matter to be voted on at the annual
meeting.
A list of
stockholders entitled to vote at the annual meeting will be available for
examination by Vishay’s stockholders during ordinary business hours for a period
of ten days prior to the annual meeting at The Rittenhouse Hotel Ballroom,
2nd Floor at 210
West Rittenhouse Square, Philadelphia, PA 19103. A stockholder list will also be
available for examination at the annual meeting.
What constitutes a quorum?
A quorum is the
minimum number of votes required to be present at the annual meeting to conduct
business. As set forth in Vishay’s by-laws, the holders of a majority of the
votes represented by the outstanding shares of common stock and Class B common
stock, voting together as a single class, present in person or represented by
proxy, will constitute a quorum for the transaction of business at the annual
meeting.
How are abstentions and broker non-votes considered?
Shares represented by
proxies that are properly marked “ABSTAIN” will be counted for purposes of
determining the presence of a quorum at the annual meeting. Abstentions are
regarded as voted shares and will have the same effect as a vote “AGAINST”
Proposal Two and the Stockholder Proposal. Abstentions will have no effect on
the election of directors under Proposal One.
Brokers holding
shares for beneficial owners in street name must vote those shares according to
specific instructions they receive from the beneficial owners. If instructions
are not received, brokers may only vote the shares, in their discretion, on
matters for which they are not precluded from exercising their discretion by the
rules of the New York Stock Exchange (“NYSE”). Under the NYSE rules, a broker is
permitted to vote shares on routine matters, which include ratifying the
appointment of independent auditors but do not include the election of directors
or stockholder proposals. Accordingly, brokers may vote in their discretion only
on Proposal Two. For your vote to be counted in the election of directors under
Proposal One or the Stockholder Proposal, you will need to communicate your
voting decisions to your bank, broker or other holder of record before the date
of the annual meeting.
A broker “non-vote”
occurs when a broker holding shares for a beneficial owner does not vote on a
particular proposal because the broker does not have discretionary voting power
with respect to that item and has not received instructions from the beneficial
owner. Broker non-votes will be counted in determining whether there is a quorum
at the annual meeting but will not be regarded as voted shares. Because the
Company has a plurality voting standard for the election of directors and the
other proposals will be determined by a majority of the votes cast, broker
non-votes will have no effect on the outcome of the vote on any of the
proposals.
2
What vote is required to approve each proposal?
Assuming a quorum is
present, the vote required and method of calculation for the proposals to be
considered at the annual meeting are as follows:
- Proposal One. The election of three directors to hold
office for terms of three years or until their successors are duly elected and
qualified requires a plurality of the votes of the shares of common stock and
Class B common stock, voting together as a single class, present in person or
represented by proxy and voted on the election of directors.
- Proposal Two. The ratification of the appointment of Ernst
& Young LLP as Vishay’s independent registered public accounting firm for
the year ending December 31, 2010 requires the affirmative vote of holders of
a majority of the votes of the shares of common stock and Class B common
stock, voting together as a single class, present in person or represented by
proxy.
- Stockholder Proposal. A stockholder proposal asking that Vishay’s
stockholders urge the Board to arrange the sale of Vishay Intertechnology,
Inc. to the highest bidder requires the affirmative vote of holders of a
majority of the votes of the shares of common stock and Class B common stock,
voting together as a single class, present in person or represented by
proxy.
How do I vote my shares? Can I vote electronically?
Please complete,
date, and sign the enclosed proxy card and return it without delay in the
enclosed envelope, which requires no additional postage if mailed in the United
States.
If you are enrolled
in our electronic proxy materials delivery service and received these proxy
materials via the Internet, you will need to follow the procedures for online
voting in order to vote your shares.
The shares
represented by the accompanying proxy will be voted as directed with respect to
each of the proposals set forth in the proxy statement, OR, if no direction is
indicated, at the recommendations of the Board of Directors.
You may either vote
“FOR ALL” or “WITHHOLD” your vote for the election of the nominees as directors
under Proposal One, or you may vote for only some of the nominees. You may vote
“FOR,” “AGAINST” or “ABSTAIN” on Proposal Two and the Stockholder Proposal.
Whether or not you
plan to attend the meeting, we strongly encourage you to vote by proxy prior to
the meeting.
Can I change my vote after I return my proxy card?
Yes. You may revoke
your proxy at any time before it is voted at the annual meeting. In order to
revoke your proxy, you may either:
- sign and timely return another
proxy card bearing a later date; or
- provide written notice of the
revocation to Vishay’s Corporate Secretary; or
- attend the annual meeting and vote
in person.
If your shares are
held in a stock brokerage account or by a bank or other nominee, you must follow
the instructions provided by your broker, bank, or nominee on how to revoke your
proxy.
3
What will happen if I provide my proxy but do not vote on a proposal?
You should provide
voting instructions for all proposals appearing on the proxy card. The persons
named as proxies on the enclosed proxy card will vote your shares according to
your instructions. However, if you fail to provide instructions on how you want
your shares to be voted, properly signed and dated proxies will be voted in
accordance with the recommendation of the Board of Directors.
What will happen if I do not provide my proxy?
If you are a
stockholder of record, your shares will not be voted.
If you are the
beneficial owner of shares held in street name, your broker, bank, or other
holder of record might be authorized to vote your shares on certain routine
matters. The NYSE considers the ratification of the independent registered
public accounting firm to be a routine matter. On this matter, your broker or
nominee can vote your street name shares on this item even though you have not
provided voting instructions, or chose not to vote your shares on these
matters.
Who will verify the election results?
Vishay will appoint
an inspector who will ascertain the number of shares outstanding and the voting
powers of each, determine the shares represented at the annual meeting and the
validity of the proxies and ballots, count all votes and ballots, determine and
retain for a reasonable period a record of the disposition of any challenges
made to any determinations by such inspector, and certify a determination of the
number of shares represented at the annual meeting and his count of all votes
and ballots.
Are there any stockholders who own more than 5% of Vishay’s shares or
voting power?
Dr. Felix Zandman,
Founder, Executive Chairman of the Board of Directors, and Chief Technical and
Business Development Officer of Vishay, directly, beneficially, and as voting
trustee under a voting trust agreement, has sole or shared voting power over
45.2% of the total voting power of Vishay’s outstanding shares of common stock
and Class B common stock and intends to vote FOR ALL nominees,
FOR Proposal Two, and AGAINST the
Stockholder Proposal.
According to filings
made with the Securities and Exchange Commission (“SEC”), LSV Asset Management,
Blackrock, Inc., and The Bank of New York Mellon Corporation own greater than 5%
of Vishay’s outstanding common stock. See “Security Ownership of Certain
Beneficial Owners and Management” for more information. LSV Asset Management,
Blackrock, Inc., and The Bank of New York Mellon Corporation have not indicated
their intentions to Vishay regarding matters to be voted on at the annual
meeting.
Who paid to send me the proxy materials?
Vishay is required to
make these materials available to you. SEC rules require that we mail a notice
to our stockholders advising that our proxy statement, annual report to
stockholders, electronic proxy card, and related materials are available for
viewing, free of charge, on the Internet. Stockholders may then access these
materials and vote over the Internet or request delivery of a full set of
materials by mail or email. We have elected to utilize this process for the 2010
annual meeting. We intend to begin mailing the required notice, called Notice of
Internet Availability of Proxy Materials, to stockholders on or about April 27,
2010. The proxy materials will be posted on the Internet, at ir.Vishay.com, no later than the day we begin mailing the
Notice.
These rules give us
the opportunity to serve you more efficiently by making the proxy materials
available quickly online and reducing costs associated with printing and
postage. If you receive a Notice, you will not receive a paper or electronic
copy of the proxy materials unless you request one, using the procedure
described in the Notice and on Vishay’s investor relations website. You may also
elect to receive the Notice for future meetings electronically, which will save
Vishay printing and mailing costs, by registering for this program at
www.icsdelivery.com/vsh or
by contacting your broker.
The cost of
solicitation of proxies will be borne by Vishay. The Board of Directors may use
the services of Vishay’s directors, officers and other regular employees to
solicit proxies personally or by telephone. Arrangements will be made with
brokerage houses and other custodians, nominees and fiduciaries to forward
solicitation material to the beneficial owners of the shares held of record by
such fiduciaries, and Vishay will reimburse them for the reasonable expenses
incurred by them in so doing.
4
GOVERNANCE OF THE COMPANY
What is corporate governance?
Corporate governance
is the process by which companies govern themselves.
At Vishay, day-to-day
business activities are carried out by our employees under the direction and
supervision of our Chief Executive Officer (“CEO”). The Board of Directors
oversees these activities. In doing so, each director is required to use his or
her business judgment in the best interests of Vishay and its stockholders. The
Board’s primary responsibilities include:
- Review of Vishay’s performance,
strategies, and major decisions;
- Oversight of Vishay’s compliance
with legal and regulatory requirements and the integrity of its financial
statements;
- Oversight of management, including
review of the CEO’s performance and succession planning for key management
roles; and
- Oversight of compensation for the
CEO, key executives and the Board, as well as oversight of compensation
policies and programs for all employees.
Additional
description of the Board’s responsibilities is included in our Corporate
Governance Principles document, which is available to stockholders on our
website and in print upon request, as described below.
Where can I find more information about the corporate governance
practices of Vishay?
Various corporate
governance related documents are available on our website. These include:
- Corporate Governance
Principles
- Code of Business Conduct and
Ethics
- Code of Ethics Applicable to the
Company’s Chief Executive Officer, Chief Financial Officer, Principal
Accounting Officer or Controller and Financial Managers
- Audit Committee
Charter
- Nominating and Corporate
Governance Committee Charter
- Compensation Committee
Charter
- Strategic Affairs Committee
Charter
- Policy on Director Attendance at
Annual Meetings
- Nominating and Corporate
Governance Committee Policy Regarding Qualification of
Directors
- Procedures for Securityholders’
Submissions of Nominating Recommendations
- Securityholder Communications with
Directors and Interested Party Communication with Non-Management
Directors
- Whistleblower and Ethics Hotline
Procedures
- Related Party Transaction
Policy
To view these
documents, access ir.Vishay.com and click on
“Corporate Governance.” Any of these documents can be obtained in print by any
stockholder upon written request to Vishay’s investor relations
department.
We intend to post any
amendments to or any waivers from, a provision of our Code of Ethics Applicable
to the Company’s Chief Executive Officer, Chief Financial Officer, Principal
Accounting Officer or Controller and Financial Managers on our
website.
What is the composition of our Board of
Directors?
Vishay has a
staggered Board of Directors divided into three classes. The number of directors
is fixed by the Board of Directors, subject to a maximum of fifteen directors as
provided in the Company’s charter documents. There are currently twelve members
of the Board. As described in Proposal One, three directors will be elected to
Class I for a term expiring at the annual meeting of stockholders in 2013.
Biographical information on each of the directors is included in Proposal
One.
5
How does the Board determine which directors are considered independent?
The Board of
Directors has determined that, to be considered independent, an outside director
may not have a direct or indirect material relationship with Vishay. A material
relationship is one which impairs or inhibits, or has the potential to impair or
inhibit, a director’s exercise of critical and disinterested judgment on behalf
of Vishay and its stockholders. The materiality standard applied by the Board
includes, but is not limited to, the disqualifying relationships set forth in
the governance listing standards of the NYSE.
Accordingly, the
Board has concluded that Frank Dieter Maier, Eliyahu Hurvitz, Dr. Abraham
Ludomirski, Wayne M. Rogers, Ronald Ruzic, and Thomas Wertheimer qualify as
independent directors. Zvi Grinfas also qualified as an independent director
during his service on the Board. Each of the Audit Committee, the Nominating and
Corporate Governance Committee, the Compensation Committee, and the Strategic
Affairs Committee of the Board is composed entirely of independent
directors.
How often did the Board meet during 2009?
The Board of
Directors met 6 times during the year ended December 31, 2009. In 2009, each
director attended at least 75% of the aggregate number of meetings of the Board
of Directors and any Committee on which such director served, except for Mr.
Hurvitz who attended 38%. In those instances when Mr. Hurvitz has been unable to
attend meetings of the Board or the Committee on which he serves, he has
communicated in advance his views on the matters to be discussed to the Chairman
of the Board or to other directors, in order to assure that his point of view on
these matters will be known to the directors. Information regarding Vishay’s
policy on director attendance at annual meetings of stockholders and the number
of directors attending last year’s annual meeting may be found on our website at
ir.Vishay.com.
What is the role of the Board’s Committees?
The Board of
Directors maintains an Executive Committee, a Nominating and Corporate
Governance Committee, an Audit Committee, a Compensation Committee and a
Strategic Affairs Committee, each of which is described below.
Executive Committee - The Executive
Committee is authorized to exercise all functions of the Board of Directors in
the intervals between meetings of the Board to the extent permitted by Delaware
law. The current chairman of the Committee is Dr. Zandman.
Nominating and Corporate Governance
Committee - The functions of the Nominating and Corporate
Governance Committee include identifying individuals qualified to become members
of the Board; selecting, or recommending that the Board of Directors select, the
director nominees for the next annual meeting of stockholders; developing and
recommending to the Board a set of corporate governance principles for Vishay;
overseeing the evaluation of the Board and the management of Vishay;
administering Vishay’s Related Party Transactions Policy; and performing other
related functions specified in the Committee’s charter. A copy of the
Committee’s charter is available to stockholders on our website and in print
upon request.
The chairman of the
Nominating and Corporate Governance Committee is designated under our Corporate
Governance Principles to preside at the executive sessions of the Board’s
non-management directors. The current chairman of the Committee is Mr. Hurvitz.
Audit Committee - The functions of the Audit Committee
include overseeing Vishay’s accounting and financial reporting processes;
overseeing the audits of our consolidated financial statements and the
effectiveness of our internal control over financial reporting; assisting the
Board in its oversight of the integrity of our financial statements, our
compliance with legal and regulatory requirements, the independence and
qualifications of our independent registered public accounting firm, and the
performance of our internal audit function and independent registered public
accounting firm; and performing other related functions specified in the
Committee’s charter. A copy of the Committee’s charter is available to
stockholders on our website and in print upon request. The Audit Committee
consists of three non-management directors, each of whom satisfies the
independence requirements of the rules of the SEC and the governance listing
requirements of the NYSE. All of the members of the Committee also satisfy the
financial literacy requirements of the NYSE and Mr. Wertheimer, the chairman of
the Committee, qualifies as an audit committee financial expert under the rules
of the SEC.
6
Compensation Committee - The functions of
the Compensation Committee include evaluating the performance of the Chief
Executive Officer and, based on this evaluation, determining and approving the
compensation of the Chief Executive Officer; making recommendations to the Board
with respect to compensation of our other executive officers; making
recommendations to the Board with respect to compensation of non-management
directors; making recommendations to the Board with respect to, and
administering, our incentive compensation plans and equity based compensation
plans; and performing other related functions specified in the Committee’s
charter. The Compensation Committee is authorized, within the limits of the 2007
Stock Incentive Program of Vishay, to determine the individuals who are to
receive grants, including stock, stock options, restricted stock and restricted
stock units, and the vesting requirements with respect to those grants, and to
administer and interpret the plan. Mr. Grinfas, who served as chairman of this
committee, will remain a member of this committee until his resignation from the
Board due to health reasons, effective May 31, 2010. As of April 18, 2010, Wayne
Rogers is the chairman of this committee. A copy of the Committee’s charter is
available to stockholders on our website and in print upon request. Also see
“Executive Compensation.”
Strategic Affairs Committee -
The functions of the
Strategic Affairs Committee include advising and making recommendations to the
Board and management with respect to potential significant acquisitions,
divestitures, joint ventures, business combinations, restructuring and other
strategic initiatives, and considering and negotiating on behalf of the Company
strategic initiatives involving the Company’s management with respect to which
actual or perceived conflicts may exist with management directors. The current
chairman of the Committee is Mr. Wertheimer. A copy of the Committee’s charter
is available to stockholders on our website and in print upon request.
Board Leadership Structure and Role in Risk
Oversight
The Board believes
that it is important to retain the flexibility to combine or separate the
responsibilities of the offices of Chairman of the Board and Chief Executive
Officer, as from time to time may be in the best interests of the Company. The
Board separated the positions of Chairman and Chief Executive Officer in 2004
when the Company’s founder and Chairman, Dr. Zandman, stepped down from his
position as our Chief Executive Officer to focus full-time on technical and
business development issues. Dr. Zandman remains significantly involved with the
Company’s Strategic Direction as our Chief Technical and Business Development
Officer. Because Dr. Zandman continues to provide the Company with strategic and
creative vision, the Company believes that it is appropriate that he serve as
Executive Chairman. At the same time, the active membership of Dr. Paul, our
Chief Executive Officer, on the Board assures our Board of the benefit of his
comprehensive knowledge of the Company's business, operations, industry
environment and competitive challenges.
Management
continually monitors the material risks facing the Company, including financial
risk, strategic risk, operational risk, and legal and compliance risk. The Board
of Directors is responsible for exercising oversight of management’s
identification and management of, and planning for, those risks. Although the
Board is ultimately responsible for risk oversight at the Company, the Board has
delegated to certain Committees oversight responsibility for those risks that
are directly related to their area of focus.
- The Audit Committee reviews our
policies and guidelines with respect to risk assessment and risk management,
including our major financial risk exposures, and oversees the steps
management has taken to monitor and control those exposures.
- The Compensation Committee
considers risk issues when establishing and administering our compensation
programs for executive officers and other key personnel.
- The Strategic Affairs Committee
reviews, advises and consults with management regarding our risk management
strategies, as well as potential significant acquisitions, divestitures, joint
ventures, business combinations, restructuring other strategic initiatives,
and issues that require independent arms-length decisions.
- The Nominating and Corporate
Governance Committee oversees corporate governance risks, including matters
relating to the composition and organization of the Board and recommends to
the Board how its effectiveness can be improved by changes in its composition
and organization.
Each of these
committees routinely reports to the Board on the management of these specific
risk areas. To permit the Board and its committees to perform their respective
risk oversight roles, individual members of management who supervise the
Company’s risk management report directly to the Board or the relevant committee
of the Board responsible for overseeing the management of specific risks, as
applicable. For this purpose, management has a high degree of access and
communication with the Board and its committees.
7
The Board believes
that full and open communication between management and the Board is essential
for effective risk management and oversight. Members of the Company’s senior
management regularly attend Board and committee meetings and are available to
address any questions or concerns raised on matters related to risk management.
The Board and its Committees exercise their risk oversight function by carefully
evaluating the reports they receive from management and by making inquiries of
management with respect to areas of particular interest to the
Board.
The following table
summarizes the composition of these committees as of April 19, 2010:
|
|
|
|
|
|
Nominating and |
|
|
|
Strategic |
|
|
Executive |
|
Audit |
|
Corporate Governance |
|
Compensation |
|
Affairs |
|
|
Committee |
|
Committee |
|
Committee |
|
Committee |
|
Committee |
|
|
(1) |
|
|
|
|
|
(2) |
|
|
Dr. Felix Zandman |
|
** |
|
— |
|
— |
|
— |
|
— |
Eliyahu
Hurvitz |
|
— |
|
— |
|
** |
|
— |
|
— |
Zvi Grinfas |
|
— |
|
* |
|
— |
|
* |
|
* |
Dr.
Abraham Ludomirski |
|
— |
|
— |
|
— |
|
* |
|
* |
Dr. Gerald Paul |
|
* |
|
— |
|
— |
|
— |
|
— |
Wayne
M. Rogers |
|
— |
|
* |
|
— |
|
** |
|
— |
Ziv Shoshani |
|
* |
|
— |
|
— |
|
— |
|
— |
Ronald
Ruzic |
|
— |
|
— |
|
* |
|
— |
|
— |
Thomas C. Wertheimer |
|
— |
|
** |
|
— |
|
* |
|
** |
Marc
Zandman |
|
* |
|
— |
|
— |
|
— |
|
— |
Ruta Zandman |
|
— |
|
— |
|
— |
|
— |
|
— |
Frank
Dieter Maier (3) |
|
— |
|
* |
|
— |
|
— |
|
* |
Number of Meetings during
2009 |
|
0 |
|
9 |
|
1 |
|
18 |
|
13 |
Actions by
Unanimous Consent in Lieu of |
|
|
|
|
|
|
|
|
|
|
Meeting during 2009 |
|
2 |
|
1 |
|
0 |
|
0 |
|
0 |
____________________
(1) |
|
The Executive Committee meets informally throughout the year to
discuss various business issues. |
|
|
|
(2) |
|
Effective April 18, 2010, Wayne M. Rogers was appointed Chairman of
the Compensation Committee. |
|
|
|
(3) |
|
Effective April 18, 2010 Frank Dieter Maier was appointed to the
Board of Directors. |
|
**Chairman
*Member |
How does the Board select nominees for the Board?
In selecting
candidates for nomination at the annual meeting of our stockholders, the
Nominating and Corporate Governance Committee begins by determining whether the
incumbent directors whose terms expire at the meeting desire and are qualified
to continue their service on the Board. We are of the view that the repeated
service of qualified incumbents promotes stability and continuity in the
boardroom, giving us the benefit of the familiarity and insight into our affairs
that our directors have accumulated during their tenure and contributing to the
Board’s ability to work as a collective body. Accordingly, it is the policy of
the Committee, absent special circumstances, to nominate qualified incumbent
directors who continue to satisfy the Committee’s criteria for membership on the
Board, who the Committee believes will continue to make important contributions
to the Board, and who consent to stand for re-election and, if re-elected, to
continue their service on the Board. If there are Board positions for which the
Committee will not be re-nominating a qualified incumbent, the Committee will
solicit recommendations for nominees from persons who the Committee believes are
likely to be familiar with qualified candidates, including members of the Board
and senior management.
The Committee may
also engage a search firm to assist in identifying qualified candidates. Where
such a search firm is engaged, the Committee sets the fees and scope of
engagement. The Committee will review and evaluate each candidate who it
believes merits serious consideration, taking into account all available
information concerning the candidate, the qualifications for Board membership
established by the Committee, the existing composition and mix of talent and
expertise on the Board and other factors that it deems relevant. In conducting
its review and evaluation, the Committee may solicit the views of management and
other members of the Board and may, if deemed helpful, conduct interviews of
proposed candidates. The Committee will evaluate candidates recommended by
stockholders in the same manner as candidates recommended by other persons,
except that the Committee may consider, as one of the factors in its evaluation
of stockholder recommended candidates, the size and duration of the interest of
the recommending stockholder or stockholder group in the equity of Vishay and
whether the stockholders intend to continue holding that interest through the
annual meeting date.
8
What qualifications must a director have?
Under a policy
formulated by our Nominating and Corporate Governance Committee, we generally
require that all candidates for director be persons of integrity and sound
ethical character; be able to represent all stockholders fairly; have no
interests that materially conflict with those of Vishay and its stockholders;
have demonstrated professional achievement; have meaningful management, advisory
or policy making experience; have a general appreciation of the major business
issues facing Vishay; have adequate time to devote to serve on the Board of
Directors; and satisfy our retirement policy for directors. A limited exception
to some of these requirements, other than the requirements of integrity and
ethics and the absence of material conflict, may be made for a holder of
substantial voting power. We also require that a majority of directors be
independent; at least three of the directors have the financial literacy
necessary for service on the audit committee and at least one of these directors
qualifies as an audit committee financial expert; at least some of the
independent directors have served as senior executives of public or substantial
private companies; and at least some of the independent directors have general
familiarity with the major industries in which we operate. Additionally, while
the Company does not have a formal policy with respect to the consideration of
diversity in identifying director candidates, the benefits of board diversity
are considered in the nominations process, including diversity of background and
experience. A detailed description of the qualifications required of candidates
for director, as well as the specific qualities or skills we believe should be
possessed by one or more directors, can be found on our website.
Can I recommend a nomination for director?
Yes. The Nominating
and Corporate Governance Committee will consider recommendations for director
nominations submitted by stockholders entitled to vote generally in the election
of directors. Submissions must be made in accordance with the Committee’s
procedures, as outlined below and set forth on our website. For each annual
meeting of our stockholders, the Committee will accept for consideration only
one recommendation from any stockholder or affiliated group of stockholders. The
Committee will only consider candidates who satisfy our minimum qualifications
for director, as summarized in this proxy statement and as set forth on our
website. In considering a stockholder recommendation, the Committee will take
into account, among other factors, the size and duration of the recommending
stockholder’s ownership interest in Vishay and whether the stockholder intends
to continue holding that interest through the annual meeting date. Stockholders
should be aware, as discussed above, that it is our general policy to
re-nominate qualified incumbent directors and that, absent special
circumstances, the Committee will not consider other candidates when a qualified
incumbent director consents to stand for re-election.
A stockholder wishing
to recommend to the Nominating and Corporate Governance Committee a candidate
for election as director must submit the recommendation in writing, addressed to
the Committee, care of our Corporate Secretary, at Vishay Intertechnology, Inc.,
63 Lancaster Avenue, Malvern, PA 19355. Submissions must be made by mail,
courier, or personal delivery. E-mailed submissions will not be considered.
Submissions recommending candidates for election at an annual meeting of
stockholders must generally be received no later than 120 calendar days prior to
the first anniversary of the date of the proxy statement for the prior annual
meeting of stockholders. In the event that the date of an annual meeting of
stockholders is more than 30 days following the first anniversary date of the
annual meeting of stockholders for the prior year, the submission must be made a
reasonable time in advance of the mailing of our proxy statement for the current
year. Each nominating recommendation must be accompanied by the information
called for by our “Procedures for Securityholders’ Submission of Nominating
Recommendations,” which is posted on our website. This includes specified
information concerning the stockholder or group of stockholders making the
recommendation and the proposed nominee, any relationships between the
recommending stockholder or stockholders and the proposed nominee and the
qualifications of the proposed nominee to serve as director. The recommendation
must also be accompanied by the consent of the proposed nominee to serve if
nominated and elected and the agreement of the nominee to be contacted by the
Committee, if the Committee decides in its discretion to do so.
How do stockholders and others communicate with the Board?
Vishay stockholders
may communicate with the Board of Directors, any Committee of the Board or any
individual director, and any interested party may communicate with the
non-management directors of the Board as a group, by delivering such
communications either in writing addressed to our Corporate Secretary at Vishay
Intertechnology, Inc., 63 Lancaster Avenue, Malvern, PA 19355; or by e-mail to
boardofdirectors@Vishay.com. Communications should not exceed 1,000 words.
9
All communications
must be accompanied by the following information: (i) if the person submitting
the communication is a securityholder, a statement of the type and amount of the
securities of Vishay that the person holds; (ii) if the person submitting the
communication is not a securityholder and is submitting the communication to the
non-management directors as an interested party, the nature of the person’s
interest in Vishay; (iii) any special interest, meaning an interest not in the
capacity as a stockholder of Vishay, of the person in the subject matter of the
communication; and (iv) the address, telephone number and e-mail address, if
any, of the person submitting the communication. Communications addressed to
directors may, at the direction of the directors, be shared with Vishay’s
management.
DIRECTOR COMPENSATION
Our non-employee
directors each received a fee of $2,500 for each individual Board or Committee
meeting attended in person, and $1,000 for each Board or Committee meeting
attended telephonically, during 2009. Concurrent with the annual meeting, each
non-employee director receives a retainer fee of $30,000 for serving on the
Board of Directors. Directors who are also employees of Vishay do not receive
any additional compensation for their service as directors. See “Executive
Compensation.”
Beginning in 2010,
our non-employee directors will each receive an annual grant of 10,000
restricted stock units.
The following table
provides information with respect to the compensation paid or provided to the
Company’s non-management directors during 2009:
|
|
Fees Earned and |
|
|
|
|
Name |
|
Paid in Cash |
|
Stock Awards (1) |
|
Total |
Zvi Grinfas |
|
$ |
90,000 |
|
— |
|
$ |
90,000 |
Eliyahu Hurvitz |
|
|
35,500 |
|
— |
|
|
35,500 |
Dr. Abraham Ludomirski |
|
|
83,500 |
|
— |
|
|
83,500 |
Wayne M. Rogers |
|
|
49,500 |
|
— |
|
|
49,500 |
Ronald Ruzic |
|
|
39,000 |
|
84,640 |
|
|
123,640 |
Thomas C. Wertheimer |
|
|
77,500 |
|
— |
|
|
77,500 |
____________________
(1) |
|
Mr. Ruzic was
granted 16,000 restricted stock units in 2009 under the Stock Incentive
Plan. As he joined the Board of Directors on January 1, 2009, Mr. Ruzic
did not receive restricted stock granted to other directors in 2008. The
restricted stock units for Mr. Ruzic vest in two equal annual
installments, beginning on the grant date. The grant-date fair value of
restricted stock awards is recognized over the vesting period. The amount
presented in the table is the grant-date fair value of the RSUs. These
awards were granted on May 26, 2009. |
Mrs. Ruta Zandman is
employed by Vishay as a public relations associate and accordingly receives no
compensation for her service on the Board of Directors. Mrs. Zandman’s salary
for 2009 was $25,000. Mrs. Zandman does not participate in any of Vishay’s
retirement or incentive compensation programs.
10
PROPOSAL ONE
ELECTION OF DIRECTORS
Three directors will
be elected to Class I for a term expiring at the annual meeting of stockholders
in 2013.
Dr. Felix Zandman,
Dr. Gerald Paul and Mr. Frank Dieter Maier are the nominees for election as
Class I Directors for terms of three years, expiring at the 2013 annual meeting
of stockholders. Each of the nominees is currently a member of the Board and has
consented to serve if elected.
If any nominee for
director becomes unavailable for election, the proxies will be voted for such
substitute nominee(s) as the Board of Directors may propose. We have no reason
to believe that any of the nominees will be unable or unwilling to serve if
elected.
The following table
summarizes the current directors:
Name |
|
Age |
|
Director Since |
|
Term Expiring |
Nominees for Election
as |
|
|
|
|
|
|
Class I Directors: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Felix Zandman (1)(2) |
|
81 |
|
1962 |
|
2013 |
Dr. Gerald Paul |
|
61 |
|
1993 |
|
2013 |
Frank Dieter Maier |
|
72 |
|
2010 |
|
2013 |
|
|
|
|
|
|
|
Class II Directors: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Eliyahu Hurvitz |
|
77 |
|
1994 |
|
2011 |
Dr. Abraham Ludomirski |
|
57 |
|
2003 |
|
2011 |
Wayne M. Rogers |
|
77 |
|
2006 |
|
2011 |
Ronald Ruzic |
|
71 |
|
2009 |
|
2011 |
|
|
|
|
|
|
|
Class III Directors: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Ziv Shoshani (1) |
|
43 |
|
2001 |
|
2012 |
Thomas C. Wertheimer |
|
69 |
|
2004 |
|
2012 |
Marc Zandman (1)(3) |
|
48 |
|
2001 |
|
2012 |
Ruta Zandman (1) |
|
72 |
|
2001 |
|
2012 |
____________________
(1) |
|
Dr.
Felix Zandman and Ruta Zandman are married. Marc Zandman is their son and
Ziv Shoshani is their nephew. |
|
(2) |
|
Executive Chairman of the Board. |
|
(3) |
|
Vice
Chairman of the Board. |
11
Nominees for Election as Class I Directors –
Terms Expiring 2013
Dr. Felix Zandman is a founder of Vishay, and has been Executive Chairman of the Board
since 1989 and a Director since Vishay’s inception in 1962. In addition to his
position as Executive Chairman, Dr. Zandman became Chief Technical and Business
Development Officer on January 1, 2005. Dr. Zandman was Chief Executive Officer
of Vishay from its inception in 1962 through December 31, 2004, when Dr. Gerald
Paul was appointed Chief Executive Officer. Dr. Zandman was President of Vishay
from its inception through March 1998. As the founder of the Company, Dr.
Zandman brings to the Board intimate familiarity with the Company’s businesses,
technologies and the industries in which it competes, as well as the strategic
and creative vision that has driven the Company’s success.
Dr. Gerald Paul was appointed Chief Executive Officer effective January 1, 2005. Dr. Paul
has served as a Director of Vishay since 1993, and has been President of Vishay
since March 1998. Dr. Paul also was Chief Operating Officer from 1996 to 2006.
Dr. Paul previously was an Executive Vice President of Vishay from 1996 to 1998,
and President of Vishay Electronic Components, Europe from 1994 to 1996. Dr.
Paul has been Managing Director of Vishay Electronic GmbH, a subsidiary of
Vishay, since 1989. Dr. Paul has been employed by Vishay and a predecessor
company since 1978. Dr. Paul possesses extensive experience with the Company,
the most detailed knowledge of our operations, including the integration of
acquired companies, and a proven understanding of the challenges facing the
Company in all aspects of the business cycle.
Frank Dieter Maier was Managing Director of TEMIC GmbH where he was responsible for the
development and concentration of electronic activities within Daimler, including
the operations of 26 semiconductor and automotive electronics plants until 2002.
He currently serves as Deputy Chairman of the Board of Directors of Varta
Microbattery GmbH, Chairman of the Board of Directors and member of the Advisory
Council of BASIC AG, a director of Preh Gmbh and a member of the Advisory
Council of BMK GmbH. Mr. Maier’s prior business experience has given him
in-depth knowledge of and experience in semiconductors and passive electronic
components.
The Board of Directors recommends that you
vote “FOR ALL” the nominees as directors.
Class II Directors – Terms Expiring 2011
Eliyahu Hurvitz was Chairman of the Board of Teva Pharmaceutical Industries Ltd., a
leading generic pharmaceutical company, until March 2010. He was President and
Chief Executive Officer of Teva from 1976 to 2002 when he stepped down from
these positions. He serves as Chairman of the Board of The Israel Democracy
Institute (IDI), Chairman of the Board of Neuro Survival Technologies Ltd., an
Israeli molecular imaging and drug development company, Chairman of the Board of
Pontifax Management (G.P) Ltd., a venture capital firm, and Chairman of the
Board of Protalix BioTherapeutics, Inc., a biotechnology company. He was a
member of the Belfer Center for Science and International Affairs at John F.
Kennedy School of Government at Harvard University from 2002 until 2005. Having
built Teva into Israel’s largest public company, Mr. Hurvitz brings to the Board
a wealth of public company experience and insight.
Dr. Abraham Ludomirski is the founder and, for more than the past
five years, managing director of Vitalife Fund, a venture capital company
specializing in high-tech electronic medical devices. He is also the Chairman of
the Board of Sightline Technologies Ltd., an Israeli high-tech company
specializing in miniature electronics and optical and video systems, and serves
on the board of directors of Medison, Trig Medical, Deep Breeze and Canfite. Dr.
Ludomirski earned his M.D. at the Sackler Tel-Aviv University Medical School,
specializing in OBGYN and completed his fellowship at the University of
Pennsylvania in maternal fetal medicine. In addition to his general familiarity
with corporate affairs and governance, Dr. Ludomirski’s work in the high-tech
venture capital and medical fields gives him a valuable perspective on
investment in innovative technologies.
Wayne M. Rogers is an
investor and regular stock commentator and analyst on Fox News Channel. For more
than the past five years, Mr. Rogers has been president of Wayne M. Rogers &
Co., an investment management firm. Mr. Rogers possesses extensive knowledge of
corporate finance and insight with respect to mergers and acquisitions as well
as general economic, business and market trends.
12
Ronald Ruzic became a director effective January 1, 2009. Prior to retiring in 2003,
Mr. Ruzic was Executive Vice President of BorgWarner
Inc. since 1992 and Group President of BorgWarner Automotive Inc. since 1989.
Previously, he held various executive positions with BorgWarner. After joining
BorgWarner in 1968 as a senior manufacturing engineer for its subsidiary Morse
Chain, Mr. Ruzic progressed through engineering and management positions and
managed various BorgWarner operations in Italy, Mexico, Germany and the United
States. Mr. Ruzic formerly served on the boards of directors of Guilford Mills
Inc., AG Kühnle Kopp & Kausch, Magneti Marelli S.p.A. and Citation
Corporation. Mr. Ruzic brings to the Board many years’ experience with the
management and technical challenges facing complex, multi-national businesses
such as the Company.
Class III Directors – Terms Expiring 2012
Ziv Shoshani has been Executive
Vice President – Vishay Precision Group since November 1, 2009. He was the Chief
Operating Officer of the Company from January 1, 2007 to November 1, 2009.
During 2006, he was the Deputy Chief Operating Officer. Mr. Shoshani served as
an Executive Vice President of the Company since 2000 with various areas of
responsibility, including Executive Vice President of the Measurements Group
Division and Foil Resistors Division. Mr. Shoshani has been employed by the
Company since 1995. Mr. Shoshani is expected to serve as the Chief Executive
Officer and President, and will also serve on the Board of Directors of Vishay
Precision Group if the intended spin-off of our foil resistors and precision
measurements businesses into an independent, publicly-traded company is
completed. He will resign his executive positions with our Company, but is
expected to remain on Vishay Intertechnology’s Board of Directors. If the
intended spin-off does not take place, Mr. Shoshani is expected to resume his
previous position as Chief Operating Officer of the Company. Mr. Shoshani is the
nephew of Dr. Felix Zandman, Vishay’s Executive Chairman and Chief Technical and
Business Development Officer. Having been involved with many aspects of the
Company’s business, Mr. Shoshani has a wide-ranging familiarity with the
Company’s operations, technology and industry environment.
Thomas C. Wertheimer is an independent
financial and accounting consultant. Prior to his retirement in 2000, he was a
senior audit partner with the accounting firm of PricewaterhouseCoopers LLP and
its predecessor Coopers & Lybrand LLP. In this capacity, Mr. Wertheimer was
responsible for the audits of major U.S. and international public companies and
was also a technical consulting partner in the firm’s national office. From 2003
until 2007, Mr. Wertheimer was a consultant for the Public Company Accounting
Oversight Board (PCAOB). He is also a director of Fiserv, Inc., an information
management and service provider, and Xinyuan Real Estate Co., Ltd., a
residential real estate developer in China. Mr. Wertheimer brings to the Board
extensive knowledge and experience in accounting, finance, risk management and
public company oversight.
Marc Zandman
has been Vice Chairman of the Board since 2003, a Director of Vishay since 2001,
and President of Vishay Israel Ltd. since 1998. Mr. Zandman was appointed Chief
Administration Officer as of January 1, 2007. Mr. Zandman was Group Vice
President of Vishay Measurements Group from 2002 to 2004. Mr. Zandman has served
in various other capacities with Vishay since 1984. Mr. Zandman is expected to
serve as the non-executive Chairman of the Board of Directors of Vishay
Precision Group if the intended spin-off of our foil resistors and precision
measurements businesses is completed. He is the son of Dr. Felix Zandman,
Vishay’s Executive Chairman and Chief Technical and Business Development
Officer. As Chief Administration Officer, Mr. Zandman has a breadth of knowledge
concerning the Company’s businesses generally and specifically with respect to
the management of its human resources and information technology, as well as
close familiarity with the Company’s Israel operations where the Company
conducts significant research and development and manufacturing activities.
Ruta Zandman has been
employed by Vishay since October 1993 as a Public Relations Associate. She is
the wife of Dr. Felix Zandman, Vishay’s Executive Chairman and Chief Technical
and Business Development Officer, and usually accompanies Dr. Zandman as a
representative of Vishay. Mrs. Zandman has shared or has contingent voting power
over approximately 25.3% of the Company’s total voting power, for which it is
deemed appropriate that she serve as a member of the Company’s Board.
Under the Company’s
Corporate Governance Principles, directors may not stand for election or
re-election after the age of 75, unless the Board makes an affirmative
determination that, because of the importance and value of the continued service
of a director, the retirement policy should be waived. Prior to their
re-election in 2008, the Board made such a determination with respect to Messrs.
Hurvitz and Rogers. This policy does not apply to Dr. Zandman or any person who
controls more than 20% of the voting power of the Company.
13
REPORT OF THE AUDIT COMMITTEE
Management is
responsible for maintaining effective internal control over financial reporting,
for assessing the effectiveness of internal control over financial reporting,
and for preparing our consolidated financial statements. Our independent
registered public accounting firm is responsible for, among other things,
performing an independent audit of our consolidated financial statements in
accordance with standards of the Public Company Accounting Oversight Board
(United States) (“PCAOB”) and issuing a report thereon. Our independent
registered public accounting firm is also responsible for auditing the
effectiveness of our internal control over financial reporting in accordance
with standards of the PCAOB, and issuing a report thereon. It is the
responsibility of the Audit Committee to monitor and oversee these processes.
In fulfilling its
oversight duties, the Audit Committee reviewed and discussed the following with
management and our independent registered public accounting firm, Ernst &
Young LLP: (a) the audited financial statements for the fiscal year ended
December 31, 2009; (b) the effectiveness of our internal control over financial
reporting; and (c) discussed with the independent auditors matters required to
be discussed under Statement on Auditing Standards No. 61, Communications with Audit Committees (SAS 61), as amended and as adopted by the
PCAOB in AU Section 380. These required communications addressed, among other
topics, the independent registered public accounting firm’s responsibility under
the standards of the PCAOB; critical accounting policies and practices;
judgments and accounting estimates; alternative accounting treatments; any
significant audit adjustments; any disagreements or difficulties encountered in
performing the audit; and other material communications between the independent
registered public accounting firm and management. The Audit Committee received
from the independent auditors written disclosures regarding the auditor’s
independence required by PCAOB Ethics and Independence Rule 3526, Communication with Audit Committees Concerning
Independence, and has
discussed with the independent auditors, the independent auditor’s independence.
The Audit Committee also considered the compatibility of non-audit services
provided to Vishay by Ernst & Young LLP, and the fees and costs billed or to
be billed for these services, with the maintenance of the independent registered
public accounting firm’s independence. The Committee has concluded that the
provision of the non-audit services by Ernst & Young LLP in 2009 did not
impair the independent registered public accounting firm’s independence. (The
fees and costs billed by the independent registered public accounting firm for
audit and non-audit services in 2008 and 2009 are shown under Proposal Two.)
Under the Audit and Non-Audit Services Pre-Approval Policy that was adopted by
the Audit Committee in May 2003, the Audit Committee must pre-approve all audit
and non-audit services provided to Vishay by the independent registered public
accounting firm. The policy sets forth the procedures and conditions for
pre-approval of these services. All of the audit and non-audit services provided
by the independent registered public accounting firm since adoption of the Audit
and Non-Audit Services Pre-Approval Policy were pre-approved by the Committee in
accordance with such policy.
Based upon the above
review and discussions with management and the independent registered public
accounting firm, the Audit Committee recommended to the Board of Directors that
our audited financial statements be included in our Annual Report on Form 10-K
for the fiscal year ended December 31, 2009 for filing with the Securities and
Exchange Commission. The Audit Committee has also appointed Ernst & Young
LLP as our independent registered public accounting firm for fiscal year 2010,
but the Committee has determined in accordance with our historical practices to
submit the appointment for ratification by stockholders (See Proposal Two).
Respectfully
submitted,
The Audit Committee
of the Board of Directors
Thomas C. Wertheimer,
Chairman
Zvi Grinfas
Frank Dieter Maier
Wayne M. Rogers
14
PROPOSAL TWO
RATIFICATION OF APPOINTMENT OF
INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
The Audit Committee
of the Board of Directors is responsible for the selection of our independent
registered public accounting firm. The Committee has determined to reappoint the
public accounting firm of Ernst & Young LLP as independent registered public
accounting firm to audit our financial statements for the fiscal year ending
December 31, 2010, as well as to audit the effectiveness of our internal control
over financial reporting. Ernst & Young LLP has served as our independent
registered public accounting firm since 1968. Although stockholder approval for
the appointment of the independent registered public accounting firm is not
required, we are continuing our practice of submitting the selection of the
independent registered public accounting firm to stockholders for their
ratification.
Representatives of
the firm of Ernst & Young LLP are expected to be present at the annual
meeting and will have an opportunity to make a statement if they so desire and
will be available to respond to appropriate questions from stockholders.
Under the Audit and
Non-Audit Services Pre-Approval Policy that was adopted by the Audit Committee
in May 2003, the Audit Committee must pre-approve all audit and non-audit
services provided to Vishay by the independent registered public accounting
firm. The policy sets forth the procedures and conditions for pre-approval of
these services. The Audit Committee has pre-approved generally the engagement of
the independent registered public accounting firm for services relating to our
filings with the SEC (including comfort letters and consents for securities
offerings); acquisition or disposition related diligence activities; internal
control review and compliance; interpretation and compliance with accounting and
accounting-related disclosure rules and standards; certain attest services;
domestic and international tax planning and compliance; and risk management.
The following table
sets forth the aggregate fees billed by Ernst & Young LLP for audit and
non-audit services rendered to Vishay in 2009 and 2008. These fees are
categorized as audit fees, audit-related fees, tax fees, and all other fees. The
nature of the services provided in each category is described following the
table.
|
|
2009 |
|
2008 |
Audit fees |
|
$ |
5,200,000 |
|
$ |
6,600,000 |
Audit-related fees |
|
|
1,600,000 |
|
|
100,000 |
Tax fees |
|
|
1,300,000 |
|
|
1,500,000 |
All other fees |
|
|
100,000 |
|
|
100,000 |
Total fees |
|
$ |
8,200,000 |
|
$ |
8,300,000 |
|
|
|
|
|
|
|
Audit fees. These fees generally consist of professional
services rendered for the audits of the consolidated financial statements of
Vishay and its internal control over financial reporting, quarterly reviews,
subsidiary or equity investment audits, issuance of comfort letters, consents,
income tax provision procedures, and assistance with and review of documents
filed with the SEC.
Audit-related fees. These fees generally consist of assurance
and other services related to the performance of the audit or review of Vishay’s
financial statements or that are traditionally performed by the independent
registered public accounting firm, issuance of consents and letters to
underwriters, due diligence related to acquisitions, internal control reviews,
attest services that are not required by statute or regulation, consultations
concerning financial accounting and reporting standards, and financial audits of
employee benefit plans. For 2009, audit-related fees are principally related to
the intended spin-off of Vishay Precision Group, Inc.
Tax fees. These fees generally relate primarily to tax
compliance, including review and preparation of corporate and expatriate tax
returns, assistance with tax audits, review of the tax treatment for certain
expenses, extra-territorial tax analysis, and tax due diligence relating to
acquisitions. They also include fees for state and local tax planning and
consultations with respect to various domestic and international tax matters.
15
All other fees. These fees generally consist of reviews for
compliance with various government regulations, risk management and treasury
reviews and assessments and audits of various contractual
arrangements.
Vishay did not make
use in 2009 of the rule that waives pre-approval requirements for non-audit
services in certain cases if the fees for these services constitute less than 5%
of the total fees paid to the independent registered public accounting firm
during the year.
The Audit Committee and the Board of Directors
recommend that you vote “FOR”
the ratification of the appointment of Ernst
& Young LLP as our independent registered
public accounting firm for the
year ending December 31, 2010.
STOCKHOLDER PROPOSAL
A stockholder has
advised us that he intends to introduce the following proposal to be considered
at the 2010 Annual Meeting of Stockholders. Mr. William Steiner, 112 Abbotsford
Gate, Piermont, NY 10968, who has advised that he held 4,000 shares of Vishay
common stock as of October 20, 2009, the date he submitted this proposal,
proposes the adoption of the following resolution, the text of which is set
forth below, together with Mr. Steiner’s supporting statement exactly as we
received it. Following the proposal, we explain why our Board recommends a vote
AGAINST the proposal. Dr. Felix Zandman, beneficial
owner of 45.2% of the total voting power of Vishay’s outstanding shares of
common stock and Class B common stock, has indicated that he intends to vote all
of these shares against this stockholder proposal.
Proposal
MAXIMIZE VALUE RESOLUTION
RESOLVED: That the
shareholders of Vishay Intertechnology, Inc. urge the Vishay Intertechnology,
Inc. Board of Directors to arrange for the prompt sale of Vishay
Intertechnology, Inc. to the highest bidder.
Supporting Statement
The purpose of the
Maximize Value Resolution is to give all Vishay Intertechnology, Inc.
shareholders the opportunity to send a message to the Vishay Intertechnology,
Inc. Board that they support the prompt sale of Vishay Intertechnology, Inc. to
the highest bidder. I believe a strong and or majority vote by the shareholders
would indicate to the board the displeasure felt by the shareholders of the
shareholder returns over many years and the drastic action that should be taken.
Even if it is approved by the majority of the Vishay Intertechnology, Inc.
shares represented and entitled to vote at the annual meeting, the Maximize
Value Resolution will not be binding on the Vishay Intertechnology, Inc. Board.
The proponent however believes that if this resolution receives substantial
support from the shareholders, the board may choose to carry out the request set
forth in the resolution:
The prompt auction of
Vishay Intertechnology, Inc. should be accomplished by any appropriate process
the board chooses to adopt including a sale to the highest bidder whether in
cash, stock, or a combination of both.
The proponent further
believes that if the resolution is adopted, the management and the board will
interpret such adoption as a message from the company’s shareholders that it is
no longer acceptable for the board to continue with its current management plan
and strategies
I urge your support,
vote for this resolution.
16
Company Response to Stockholder Proposal
The Board believes
the proposed action is not in the best interest of Vishay or its stockholders.
While the Board agrees that its primary obligation is to maximize long-term
shareholder value, the Board unanimously opposes the view that the way to
maximize value is to put the Company up for sale in an auction
process.
The Board
continuously reviews the Company’s business to determine how to maximize value
for its stockholders, and considers all strategic and tactical options,
including the conditions under which a sale of the Company should be considered.
The Board regularly seeks to maximize stockholder value through internal growth,
improved efficiencies, expansion and better penetration of markets, acquisitions
which are complementary to our business and, currently, the spin-off of Vishay
Precision Group. We have pursued a business strategy that consists of several
elements. We have expanded within the electronic components industry, primarily
through the acquisition of other manufacturers of electronic components that
have established positions in major markets, reputations for product innovation,
quality, and reliability, strong customer bases, and product lines with which we
have substantial marketing and technical expertise. We have reduced selling,
general, and administrative expenses through the integration or elimination of
redundant sales offices and administrative functions at acquired companies. We
have achieved significant production cost savings and synergies through the
transfer and expansion of manufacturing operations to countries such as the
Czech Republic, India, Israel, Malaysia, Mexico, the People’s Republic of China,
and the Philippines, where we can benefit from lower labor costs and available
tax and other government-sponsored incentives. We have maintained significant
production facilities in those regions where we market the bulk of our products
in order to enhance the service and responsiveness that we provide to our
customers. We have used our research and development (“R&D”), engineering,
and product marketing resources to continually roll out new and innovative
products. Finally, we have strengthened our relationships with customers and
strategic partners by providing broader product lines and superior service.
Despite the
unprecedented global recession experienced in 2009, the Company continued to
generate strong cash flows. We have generated cash flows from operations in
excess of $200 million in each of the past 8 years, and cash flows from
operations in excess of $100 million in each of the past 15 years. In addition,
during the recession, the Company positioned itself for future increased
profitability. Since the beginning of the economic downturn, we have drastically
reduced our fixed costs lowering our break-even point permanently by
approximately $400 to $500 million. Our defined restructuring programs have been
implemented or announced, which will result in low restructuring charges going
forward.
The Board believes it
can function most effectively when strategic planning is conducted
confidentially and intends to continue its practice of diligently evaluating and
pursuing alternatives to enhance stockholder value. The Board believes that the
adoption of Mr. Steiner's proposal is not necessary, will be a waste of
stockholder resources, and could seriously injure the stockholders' financial
interests.
For these reasons, the Board of Directors
recommends that you vote “AGAINST” this proposal.
17
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL
OWNERS AND MANAGEMENT
On April 19, 2010,
Vishay had outstanding 172,288,582 shares of common stock, each of which
entitles the holder to one vote, and 14,352,839 shares of Class B common stock,
each of which entitles the holder to 10 votes. Voting is not
cumulative.
The following table
shows the number of shares of Vishay common stock and Class B common stock
beneficially owned by (a) each director and director nominee, (b) each “Named
Executive Officer” identified under “Executive Compensation,” (c) the directors
and executive officers of Vishay as a group and (d) any person owning more than
5% of Vishay common stock or the Class B common stock.
|
|
Common Stock |
|
Class B Common Stock |
|
|
|
|
|
|
|
|
|
Right to |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquire |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ownership |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restricted |
|
Under |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Units |
|
Options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scheduled to |
|
Exercisable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares of |
|
Vest within |
|
within 60 |
|
Percent of |
|
Shares of |
|
Percent of |
|
Voting |
Name |
|
|
Stock |
|
60 days |
|
days |
|
Class |
|
Stock |
|
Class |
|
Power |
Directors and Executive
Officers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Felix Zandman |
|
28,153 |
|
14,000 |
|
132,000 |
|
* |
|
|
14,261,316 |
(1) |
|
99.4 |
% |
|
45.2 |
% |
Zvi Grinfas |
|
17,000 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Eliyahu Hurvitz |
|
27,996 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Dr. Abraham Ludomirski |
|
17,000 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Dr. Gerald Paul |
|
80,670 |
|
9,334 |
|
88,001 |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Wayne M. Rogers |
|
37,342 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Ronald Ruzic |
|
8,000 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Ziv Shoshani |
|
85,708 |
|
1,667 |
|
24,501 |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Thomas C. Wertheimer |
|
17,400 |
|
8,000 |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Dr. Lior Yahalomi |
|
— |
|
— |
|
23,335 |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Marc Zandman |
|
7,610 |
|
1,667 |
|
24,501 |
|
* |
|
|
1,500 |
(2) |
|
* |
|
|
* |
|
Frank Dieter Maier |
|
600 |
|
— |
|
— |
|
* |
|
|
— |
|
|
— |
|
|
* |
|
Ruta Zandman |
|
1,159 |
|
— |
|
— |
|
* |
|
|
8,000,100 |
(3) |
|
55.7 |
% |
|
25.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Directors and Executive
Officers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
as a group (13
Persons) |
|
328,638 |
|
74,668 |
|
292,338 |
|
* |
|
|
14,262,816 |
|
|
99.4 |
% |
|
45.4 |
% |
c/o
Vishay Intertechnology, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63
Lancaster Avenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Malvern, PA 19355 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LSV Asset Management. (4) |
|
9,443,766 |
|
— |
|
— |
|
5.5 |
% |
|
— |
|
|
— |
|
|
3.0 |
% |
1 N. Wacker Drive, Suite 4000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chicago, IL 60606 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BlackRock, Inc. (5) |
|
18,228,341 |
|
— |
|
— |
|
10.6 |
% |
|
— |
|
|
— |
|
|
5.8 |
% |
40 East 52nd
Street |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, NY 10022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bank of New York Mellon Corp (6) |
|
15,664,905 |
|
— |
|
— |
|
9.1 |
% |
|
— |
|
|
— |
|
|
5.0 |
% |
One Wall Street, 31st Floor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New York, New York 10286 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
____________________
* Represents
less than 1% of the outstanding shares of such class or the total voting power,
as the case may be.
18
(1) |
|
Includes 616,734 shares of Class B common stock directly owned by
Dr. Felix Zandman; 8,000,100 shares held in family trusts, of which Dr.
Zandman is the trustee and over which Dr. Zandman shares voting and
dispositive control with Mrs. Ruta Zandman; and 5,644,482 shares held in a
voting trust, of which Dr. Zandman is the trustee and over which Dr.
Zandman has sole voting control. The shares held in the voting trust
consist of 3,134,074 shares deposited by the Estate of Mrs. Luella B.
Slaner and 2,510,408 shares deposited by Mrs. Slaner’s children and
various trusts for the benefit of Mrs. Slaner’s children and
grandchildren. The voting trust agreement that governs the voting trust
will remain in effect until the earlier of (x) February 1, 2050 or (y) the
death or resignation or inability to act of Dr. Zandman, but will
terminate at any earlier time upon the due execution and acknowledgment by
the trustee of a deed of termination, duly filed with the registered
office of Vishay. |
|
(2) |
|
Includes 750 shares of Class B common stock directly owned by Marc
Zandman and 750 shares of Class B common stock owned by Marc Zandman’s
minor child. |
|
(3) |
|
Includes the same 8,000,100 shares of Class B common stock held in
family trusts, of which Dr. Felix Zandman is the trustee and over which
Mrs. Zandman shares voting and dispositive control with Dr. Zandman.
Excludes 616,734 shares of Class B common stock directly owned by Dr.
Zandman; however, Mrs. Zandman has the authority to vote Dr. Zandman’s
directly owned Vishay shares in the event of his incapacity. |
|
(4) |
|
Based
on information provided in a Schedule 13G filed on February 11, 2010 by
LSV Asset Management. According to the Schedule 13G, LSV Asset Management
may be deemed to have sole power to vote or direct the vote with respect
to 9,443,766 shares of common stock; and sole power to dispose or direct
the disposition with respect to 9,443,766 shares. |
|
(5) |
|
Based
on information provided in a Schedule 13G filed on January 7, 2010 by
BlackRock, Inc.. According to the Schedule 13G, BlackRock, Inc. may be
deemed to have sole power to vote or direct the vote with respect to
18,228,341 shares of common stock; sole power to dispose or direct the
disposition with respect to 18,228,341 shares. |
|
(6) |
|
Based
on information provided in a Schedule 13G filed on February 4, 2010 by The
Bank of New York Mellon Corporation. According to the Schedule 13G, The
Bank of New York Mellon Corporation may be deemed to have sole power to
vote or direct the vote with respect to 14,113,043 shares of common stock,
and shared power to vote or direct the vote with respect to 2,820 shares;
and sole power to dispose or direct the disposition with respect to
15,355,010 shares, and shared power to dispose or direct the disposition
with respect to 5,980 shares. |
Section 16(a) Beneficial Ownership Reporting
Compliance
Section 16(a) of the
Securities Exchange Act of 1934, as amended, requires our directors and
executive officers and persons who beneficially own more than ten percent of our
common stock to report their ownership of and transactions in our stock in
filings with the SEC. Copies of these reports are also required to be supplied
to Vishay. Vishay believes, based solely on a review of the copies of such
reports received, that our directors and executive officers and persons who
beneficially own more than ten percent of our common stock complied with all
applicable Section 16(a) reporting requirements during the year ended December
31, 2009, except that Mr. Rogers inadvertently failed to timely report on Form 4
the purchase of 2,000 shares of common stock on December 16, 2009. The Form 4
related to this purchase was filed on February 24, 2010.
Compensation Committee Interlocks and Insider
Participation
No member of the
Compensation Committee was at any time during 2009 an officer or employee of
Vishay or any of the Company’s subsidiaries nor was any such person a former
officer of Vishay or any of the Company’s subsidiaries. In addition, no
Compensation Committee member is an executive officer of another entity at which
one of the Company’s executive officers serves on the board of directors.
19
EXECUTIVE COMPENSATION
Information Concerning Executive Officers
The named executive
officers of Vishay, along with their respective ages and positions with Vishay,
as of April 19, 2010, are as follows:
Name |
|
Age |
|
Position |
Felix Zandman* |
|
81 |
|
Executive Chairman of the Board, Chief
Technical and Business Development Officer |
Gerald Paul* |
|
61 |
|
Chief Executive Officer, President and Director |
Marc Zandman* |
|
48 |
|
Vice Chairman of the Board, Chief
Administration Officer, President – Vishay Israel Limited |
Lior Yahalomi |
|
51 |
|
Executive Vice President and Chief Financial Officer |
Ziv Shoshani* |
|
43 |
|
Executive Vice President – Vishay
Precision Group, and
Director |
____________________
* |
|
Biography is
provided with Board of Directors.
|
Dr. Lior Yahalomi was appointed Executive Vice President and
Chief Financial Officer of the Company effective September 1, 2008. Dr. Yahalomi
has been employed by the Company since 2006 and was Senior Vice President –
Mergers and Acquisitions, from June 2006 to September 2008. Dr. Yahalomi held
several executive positions in the technology, financial services, and venture
capital industries, including Managing Partner of CMGI’s @Ventures Technology
Fund, Vice President for New Ventures of Gateway, and Senior Vice President for
Global Business Development of a business unit of GE Capital.
Officers serve, at
the discretion of the Board of Directors, until the meeting of the Board of
Directors next following each annual meeting of stockholders, subject to their
rights under any contracts of employment described under “Compensation
Discussion and Analysis.”
Compensation Discussion and Analysis
Overview
The Compensation
Committee of the Board of Directors is responsible for establishing and
approving the compensation of the Chief Executive Officer, recommending to the
Board of Directors the compensation of other executive officers, and
administering Vishay’s incentive compensation and equity based plans. Other than
with respect to the Chief Executive Officer, the Board of Directors makes the
final determination with respect to compensation of Vishay’s named executive
officers.
This section of the
proxy statement explains how our executive compensation is designed with respect
to our executive officers.
Compensation Philosophy
Generally
Vishay’s compensation
programs were historically designed to support our business goals and promote
the short and long-term profitable growth of the Company. Vishay’s equity plans
are designed to ensure that executive compensation programs and practices are
aligned with the long-term interests of Vishay’s stockholders. Total
compensation of each individual varies with individual performance and Vishay’s
overall performance in achieving financial and non-financial objectives.
The Compensation
Committee and Vishay’s management believe that compensation should help to
recruit, retain, and motivate key employees who can function effectively both in
periods of recession and economic upturn. Ordinarily an executive officer’s
total compensation should consist of a combination of cash payments and equity
awards, to achieve the right balance between short and long term performance.
Equity-based compensation should serve to align the interests of management with
those of stockholders. Severance protection should provide executives with an
appropriate level of job security, commensurate with their contributions to the
Company and their tenure.
20
The Compensation
Committee, in consultation with Dr. Paul in his capacity as Chief Executive
Officer, undertakes an annual review of the compensation arrangements of
Vishay’s executive officers.
Performance Philosophy
The Company’s
compensation philosophy is intended to dovetail with its philosophy of
evaluating operating performance.
Like its peers in the
electronics industry, the Company has historically gauged its overall
performance in accordance with what it terms “adjusted net income.” The Company
uses this term to mean net income determined in accordance with U.S. generally
accepted accounting principles (“GAAP”) adjusted for various items that
management believes are not indicative of the intrinsic operating performance of
the Company’s business, as detailed below. The bonuses for the most senior
executive officers under the Company’s cash bonus plan discussed below,
including Dr. Zandman and Dr. Paul, were keyed to this performance metric. If
the Company performed well, these executives would earn the preponderant share
of their compensation through the bonus mechanism.
The bonuses for the
Company’s other senior executive officers, historically Mr. Marc Zandman and Mr.
Shoshani and currently including Dr. Yahalomi, have been tailored to their
specific responsibilities, although reflecting in part certain aspects of the
Company’s overall performance as well.
The Compensation
Committee has always believed that the elements of compensation for the
Company’s senior executives reward intrinsically sound management decisions and
do not encourage risk taking to enhance short-term profitability at the expense
of the long-term health and viability of the enterprise. While the design of our
executive compensation program is primarily performance-based, we do not believe that it encourages
excessive risk-taking. The Committee believes that the Company’s
senior executives have in fact at all times taken a prudent approach to
corporate risk management.
In addition, the Company has in
place a risk management program designed to identify, evaluate and control
risks. Through this program, we take a company wide view of risks and have a network of systems and oversight to insure
that risks are not viewed in isolation and are appropriately controlled and
reported, including a system of reporting to the full Board and its committees.
We believe that our compensation programs work within this system.
Historical Build of Senior Executive
Compensation Packages
In 2004, under the
direction of its Compensation Committee, the Vishay Board of Directors engaged
in a major review and overhaul of the compensation practices for its named
executive officers. In connection with this review, the Compensation Committee
engaged Mullin Consulting, currently MullinTBG, a nationally known and
recognized executive compensation consulting firm. Mullin was retained to assist
in developing appropriate benefits and compensation plans for the Company’s top
executives. Mullin made recommendations concerning the proposed terms of the
executives’ employment contracts, including particularly salary and bonus
compensation, deferred compensation arrangements, severance arrangements and
other supplemental and post-retirement benefits. Mullin performed an analysis
comparing the then current compensation of Vishay’s senior executive officers
with those of its closest peers in the passive and semiconductor component
industries. The Compensation Committee was also in regular communication with
Vishay senior executives concerning this project. As a consequence of this
review, Vishay entered into comprehensive employment agreements and other
arrangements with each of its named executive officers. Except with respect to
Dr. Zandman, whose employment agreement was amended and restated in 2009, and
the changes in executive positions discussed below, these agreements and
arrangements, except for base salaries, remained unchanged and governed the
compensation paid and awarded to the executive officers from 2004 and through
the year ended December 31, 2009. In March 2010, the Compensation Committee
approved certain changes in the employment arrangements for Dr. Paul, and the
Board approved certain changes in the employment arrangements of Dr. Zandman,
Marc Zandman, and Dr. Yahalomi, upon the recommendation of the Compensation
Committee. These arrangements (other than changes in base salaries) are expected
to be included in amendments to the employment agreements of these executive
officers.
21
The Compensation
Committee crafted the compensation packages for Vishay’s executive officers with
a view to the roles that each was expected to play over the medium term in
Vishay’s operations, development, and strategic planning. Over the past years,
the executives (with the exception of Mr. Shoshani, as will be described further
below) have continued to function in the anticipated roles so the Compensation
Committee believes that the determinations made in 2004 continue to be relevant
and appropriate to our compensation philosophy.
Although Dr. Zandman
was our Chief Executive Officer in 2004, it was contemplated that he would
relinquish that position to focus full time on technical and business
development issues. This occurred effective January 1, 2005. Vishay has always
viewed its internal growth through technical advance and its external growth
through strategic acquisitions as the primary drivers of stockholder value. Dr.
Zandman had been responsible for these areas in the past and, because he would
remain with these responsibilities going forward, the Compensation Committee
determined that it was appropriate for Dr. Zandman’s compensation to continue to
reflect his role as chief architect of our growth and success.
Dr. Paul works
closely with Dr. Zandman, has senior responsibilities for our overall business,
and has been instrumental as well in promoting our strategic advances. With the
assumption by Dr. Paul of the duties of the Chief Executive Officer in 2005,
certain responsibilities shifted from Dr. Zandman to Dr. Paul, but the
collective leadership function of the most senior executives remained intact.
The compensation of Dr. Paul reflects his position and responsibilities at the
most senior executive level.
Our succession plan
provides for the transition of Mr. Marc Zandman into the role of Chief Executive
Officer upon the eventual retirement of Dr. Paul. If Dr. Paul were unexpectedly
unable to continue as Chief Executive Officer, it is anticipated that Dr.
Zandman and Mr. Marc Zandman would serve as co-CEOs for a period of time. As
part of the transition, the Company would also intend to fill the position of
Chief Operating Officer with a strong candidate from operating management. The
responsibilities of Mr. Marc Zandman have been increasing in connection with his
gradual transition into the role of senior management, with Mr. Marc Zandman
having become Vice Chairman and Chief Administration Officer of the Company. The
compensation of Mr. Marc Zandman is intended to reflect this transitional
status. Currently, Mr. Marc Zandman reports to Dr. Paul and his compensation in
part is subject to Dr. Paul’s annual performance assessment.
Mr. Shoshani
relinquished his position as Chief Operating Officer on November 1, 2009 to
become Executive Vice President of the Vishay Precision Group. Mr. Shoshani is
expected to serve as the Chief Executive Officer and President, and will also
serve on the Board of Directors of Vishay Precision Group if the intended
spin-off of our foil resistors and precision measurements businesses into an
independent, publicly-traded company is completed. He will resign his executive
positions with our Company, but is expected to remain on Vishay
Intertechnology’s Board of Directors. If the intended spin-off does not take
place, Mr. Shoshani is expected to resume his previous position as Chief
Operating Officer of the Company.
The compensation
arrangements were embodied in agreements with each of the executives with the
expectation that they would remain in place for a period of time. The agreements
have an evergreen feature, whereby at the end of each year another year is added
so that effectively the agreements always have three remaining years in their
term. An evergreen term is essentially similar to the right of an executive to
receive severance if the Company does not renew his employment agreement at the
end of its stated term, a not uncommon feature in senior executive employment
arrangements. The Compensation Committee chose to include the evergreen feature
rather than a right to severance upon end-of-term non-renewal in recognition of
the long-standing affiliation of each of the senior executives with the Company,
their significant contributions to the growth of the Company over the years and
the expectation that their affiliation with the Company would continue for the
foreseeable future. As a consequence, the compensation arrangements can only be
modified with the respective executives’ consent, without which, the executive
would otherwise have the right to terminate employment and receive severance
pay. Given the longstanding employment relationship with and other ties to
Vishay of each of the executives, the Compensation Committee did not believe
that the evergreen feature would impede change in the executive compensation
structure for senior management, where such change would be desirable and in the
best interests of Vishay.
Dr. Yahalomi’s
employment contract was negotiated subsequent to his appointment as Executive
Vice President and Chief Financial Officer effective September 1, 2008. The
agreement was approved by the Compensation Committee and the full Board on
December 5, 2008, just as the contours of worldwide economic crisis were
beginning to come into focus. The terms of the agreement, which are discussed
below, reflect Dr. Yahalomi’s more limited history with the Company.
Accordingly, there is no evergreen feature, and the severance provisions are
scaled back.
22
Response to the Global
Recession
The nearly
unprecedented disruption in the global economy that began in the latter half of
2008 and continued into 2009 had a profound effect upon the Company. The
Compensation Committee, like the Company generally, focused on measures to see
the Company safely through the economic storm raging worldwide, and particularly
in the markets served by the Company. While management has always been focused
on generating free cash, which the Company defines as cash flow from operations
less cash used for capital expenditures, net of proceeds from sale of fixed
assets, conservation and generation of cash was central to the Company’s
short-term management objectives. The Company undertook various initiatives to
conserve cash, including plant closures and reductions in labor force.
Consistent with these measures, the Company imposed a freeze on compensation,
where possible, and the elimination of bonuses for 2009.
The Compensation
Committee froze base salaries for the Company’s senior executive officers for
2009. While Dr. Zandman and Dr. Paul have a contractual entitlement to
participation in the Company’s cash bonus plan, the Committee encouraged these
executives to forgo their cash bonuses for 2009. Drs. Zandman and Paul would
have been entitled to bonuses of $97,757 and $32,586, respectively, pursuant to
their employment agreements. At their discretion, Dr. Zandman and Dr. Paul
decided to forego their cash bonuses for 2009. Other senior executive officers,
whose bonuses are subject to individual performance measures, were not paid
bonuses for 2009. The Committee also did not make any discretionary awards of
equity-based compensation for 2009, in part because of the unsettled economic
environment and because of the depressed price of the Company’s
stock.
Role of the Compensation Consultant
During fiscal 2009,
the Compensation Committee hired PricewaterhouseCoopers (“PwC”) to assist in
respect of an evaluation of the compensation of Vishay’s executive officers. PwC
provided the Committee with data on compensation practices at companies
comparable to the Company in terms of size, industry and other characteristics.
PwC also made recommendations to the Committee concerning changes to the current
compensation packages of the executive officers, particularly with respect to
equity-based compensation. The PwC consultants that performed the consulting
services reported directly to the Committee.
PwC was also engaged
by the Compensation Committee and the Strategic Affairs Committee of the Board,
together with another consulting firm, to advise with respect to the
compensation for senior management of Vishay Precision Group following the
proposed spin-off of the Company’s foil resistor and precision measurements
businesses.
Compensation Components
The discussion that
follows in this section addresses the executive compensation packages in effect
in 2009.
The components of the
compensation packages for our named executive officers, as prescribed by their
employment agreements, include base salary, commensurate with the roles and
responsibility of the executives discussed above; annual performance based
bonuses; deferred compensation; and customary welfare and retirement benefits.
The Compensation Committee also considers the award of extra-contractual
equity-based compensation on a year-by-year basis. The basic compensation
packages for the executive officers have generally been congruent, with certain
variations reflecting their respective positions and tenure with the
Company.
The Committee
reviewed data on compensation practices of 47 public companies that are similar
to Vishay in terms of revenues, number of employees, market capitalization,
geographic location and/or scope of international operations, and that are found
in the Fortune 1000 listing and the S&P MidCap 400 Index. These companies
include several active in the semiconductor and electronic components industry,
and others in different industries. However, the Committee did not select a
specific peer group for these purposes or perform a quantitative benchmarking
analysis.
23
Based on the data it
reviewed and the performance of the Company’s executive officers, the
Compensation Committee believes that the compensation packages for 2009, taken
as a whole, continued to be generally in line with compensation arrangements at
comparable public companies. The Compensation Committee noted that the cash
compensation paid to Drs. Zandman and Paul was generally higher than the cash
compensation paid to executives at other comparable public companies, while the
equity based compensation was lower. This has been consistent with the Company’s
historical emphasis on cash compensation, as discussed below under “Incentive
Compensation.” The compensation packages of Messrs. Marc Zandman and Shoshani
have been somewhat lower than the compensation of executive officers of their
rank at other comparable public companies in consideration of their transitional
status in the Company’s management structure.
The compensation
packages for the Company’s senior executives also include severance benefits
that the Compensation Committee believes are consistent with severance programs
for similarly situated senior executives at comparable public
companies.
Base salary
The minimum base
salary levels for Drs. Zandman and Paul and Messrs. Marc Zandman and Shoshani
were fixed in the 2004 employment agreements. Dr. Zandman’s base salary has
remained unchanged since 1998, at his request. The Compensation Committee
determined the minimum base salaries in 2004 in consultation with Mullin
Consulting, based upon the executives’ salary levels in effect at the time, then
present responsibilities and expectations with respect to future
responsibilities and a comparison to peer group executive salaries. The
Compensation Committee selected the group of peer group companies on the advice
of Mullin Consulting. Compensation practices in the peer group were only one of
the factors considered by the Compensation Committee, and the Committee did not
perform a quantitative benchmarking analysis.
The Compensation
Committee reviews the base salary levels each year to determine whether an
increase would be appropriate. In this process, the Compensation Committee
considers the individual performance and prior years’ compensation level of each
of the executives, our recent operating results, operating results of our
competitors, projections for the future, other components of the executive pay
packages, perceived salary trends in executive base salary among our peer group
and, in the case of executives other than Drs. Zandman and Paul, input from our
Chief Executive Officer on executive performance.
Base salaries for Dr.
Paul and Messrs. Marc Zandman and Shoshani remained the same through 2005. For
2006, the Compensation Committee approved a revised base salary for Dr. Paul,
and, on the recommendation of the Compensation Committee, the Board increased
the base salaries of the other named executive officers other than Dr. Zandman.
These base salaries were again increased in 2007. Dr. Paul’s base salary has
always been denominated in euro, and, beginning in 2007, the base salaries of
Messrs. Marc Zandman and Shoshani have been denominated in Israeli shekels. A
portion of the increase in the salaries of Dr. Paul, Messrs. Marc Zandman and
Shoshani since 2005, expressed in terms of U.S. dollars, reflects the
significant weakening of the dollar against the currencies of the home
jurisdiction of these executives.
Incentive compensation
Dr. Zandman and Dr.
Paul participate in the Vishay Intertechnology Section 162(m) Cash Bonus Plan
(the “162(m) Plan”) based on “adjusted net income,” as described
below.
Over many years, we
have viewed adjusted net income as the primary indicator of the performance of
our senior management team. As more specifically addressed below, adjusted net
income refers to net income determined in accordance with GAAP, adjusted to
eliminate the after tax effects of items, positive or negative, that do not
relate to our intrinsic operations. These items include, among others, goodwill
impairment; impairment of indefinite-lived intangible assets; asset write-downs;
severance and restructuring costs; special tax items; and other items, such as
unusual gains or losses that impact GAAP net income, not reflecting on-going
operating activities. We utilize this measure in part because it eliminates
factors that mask the actual performance of on-going operations and because of
its currency with other public companies in our industry. Accordingly, the
Compensation Committee determined that the incentive compensation of Drs.
Zandman and Paul should be primarily in the form of a percentage of adjusted net
income, with a cap (generally three times salary) or other feature to avoid
compensation that in fact or in appearance might be deemed
excessive.
24
The 162(m) Plan
provides an annual bonus as a percentage of our adjusted net income. Dr.
Zandman’s bonus is equal to 3.0% of adjusted net income and the bonus of Dr.
Paul is equal to 1.0% of adjusted net income. Bonuses under the 162(m) Plan are
limited to three times the executive’s base salary.
Messrs. Marc Zandman
and Shoshani are eligible for a performance bonus of up to 42.5% of their
respective base salaries, as determined by the Compensation Committee, based on
their individual performances. The individual performance goals are established
by the Chief Executive Officer in consultation with the executives themselves at
the beginning of each calendar year and include both a quantitative and
qualitative component. The performance of each executive is reviewed by the
Chief Executive Officer and the Compensation Committee following the end of the
year, and each executive is assigned a performance score for each of several
categories. The total maximum score that each of Messrs. Marc Zandman and
Shoshani could achieve is 42.5, which would entitle Messrs. Marc Zandman and
Shoshani to a performance bonus of 42.5% of their base salary.
Equity Based Compensation
In recent years, the
Compensation Committee was not inclined to award significant amounts of
equity-based compensation, and the 2004 employment arrangements with our
executive officers reflect this approach. In part, the Compensation Committee’s
determination not to rely on equity-based compensation was motivated by a desire
to avoid dilution of the interests of stockholders generally. Also, this
approach is a reflection of our stock performance, which in recent years, in the
view of the Compensation Committee, has not accurately mirrored our operating
performance in comparison to our peers. The Compensation Committee has
reconsidered this policy and intends to consider the award of extra-contractual
equity-based compensation on a year-by-year basis. The reconsideration has been
motivated in part by the goal of aligning executive compensation with the
Company’s stock performance, which has lagged over the past several years, and
in part by limitations on the amount of incentive compensation payable under the
Company’s 162(m) cash bonus plan. When the Compensation Committee recommended
adoption of amendments to the Company’s 162(m) plan in 2004, limiting payments
to three times base salary, the Compensation Committee contemplated levels of
adjusted net income (the basis for payments under the 162(m) plan) in the range
of $100 million. In 2006 and 2007, the Company’s adjusted net income
significantly exceeded $100 million and the Compensation Committee determined
that additional incentive compensation was appropriate. No extra-contractual
equity compensation was awarded for performance in 2008 and 2009.
Deferred compensation
Executives are
eligible to participate in a nonqualified deferred compensation plan, which is
available to all employees who meet certain criteria under the Internal Revenue
Code. Vishay annually contributes $150,000 to this plan on behalf of Dr.
Zandman, and $100,000 for Dr. Paul and Messrs. Marc Zandman and Shoshani,
pursuant to their respective employment agreements.
Amounts contributed
to these plans prior to January 1, 2005 were deemed deferred until retirement or
termination of employment. Effective January 1, 2005, all employees that
participate in the plan were given the option to choose shorter deferral periods
for all or a portion of their deferred compensation. The senior executives have
elected to defer all eligible amounts of compensation until retirement or
termination of employment, at which time, the amounts would be paid in a lump
sum. To the extent required to avoid tax penalties, the deferred amounts are not
paid until six months after the termination of employment.
As noted, Drs.
Zandman and Paul and Messrs. Marc Zandman and Shoshani each have a long-standing
relationship with the Company, and, with the exception of Mr. Shoshani who is
expected to terminate his employment with the Company and become the Chief
Executive Officer of Vishay Precision Group, Inc. following the contemplated
spin-off from the Company, we expect that each will continue to serve Vishay for
so long as their services are desired and they can make effective management
contributions. The Compensation Committee therefore considers this deferred
compensation in the nature of a retirement benefit and an anticipatory reward
for loyalty to Vishay over time. The deferral is also intended to delay payment
until such time as the compensation should be deductible under Section 162(m) of
the Internal Revenue Code.
While deferred,
amounts are credited with “earnings” based on the performance of notional
investment options available under the plan. No portion of the earnings credited
during 2009 was “above market” or “preferential.”
25
Phantom stock units
Pursuant to their
employment agreements, Drs. Zandman and Paul and Messrs. Marc Zandman and
Shoshani receive annual grants of phantom stock units. The grants are made under
the Company’s Senior Executive Phantom Stock Plan, which was approved by
stockholders at our 2004 annual meeting. Similar to the deferred cash
compensation described above, the Compensation Committee considers the grant of
phantom stock units in the nature of a retirement benefit and an anticipatory
reward for loyalty to Vishay over time.
Deferred equity
compensation consists of 5,000 phantom stock units per year to each executive.
The number of units to be granted annually was determined based on the market
price of Vishay common stock in 2004, at the time the deferred compensation
program was crafted, of approximately $20 per share, so that the deferred cash
and stock compensation would be of similar magnitude. The cumulative increase in
the number of phantom stock units held by the executives over time also is
intended to strengthen the alignment of executive and stockholder interests in
the long term appreciation of Vishay’s equity value.
Severance
The Compensation
Committee believes that severance payments in the event of an involuntary
termination of employment are part of a standard compensation package for senior
executives. Also, the changes in management roles anticipated when the
compensation program was developed in 2004 may have created some uncertainty
regarding the continuity of employment of the executives other than Dr. Zandman.
Consequently, the Compensation Committee included customary severance provisions
for the named executive officers in their employment contracts. The terms of
these severance provisions are discussed elsewhere in this proxy
statement.
Dr. Zandman’s Employment
Contract
The Company entered
into an amended and restated employment agreement with Dr. Zandman, effective as
of May 13, 2009. This agreement amended and restated the employment agreement
between the Company and Dr. Zandman that was previously amended and restated as
of January 1, 2004. The amended employment agreement eliminates Dr. Zandman’s
right to receive substantial royalty payments upon the termination of his
employment in certain circumstances, as described below, and replaces it with a
series of significantly reduced payments payable to him in six annual
installments.
The 2004 employment
agreement included a provision entitling him to a royalty during the ten years
following his termination of employment equal to 5% of gross sales, less returns
and allowances, of Vishay products incorporating patents, inventions and any
other form of technology created, discovered or developed by him or under his
direction. The royalty was payable in the event Dr. Zandman was terminated
without “cause” or resigned for “good reason,” as defined in the 2004 employment
agreement. This provision was carried over from Dr. Zandman’s original
employment agreement of March 1985, and could not be modified or eliminated
without Dr. Zandman’s consent. It was a reflection, among other things, of Dr.
Zandman’s key role in the founding of the Company and creating, developing and
commercializing the Company’s technologies and the absence of any compensation
to Dr. Zandman for the core intellectual property that he has contributed to the
Company over the years from its inception.
The Company engaged a
consultant in 2007 to assist its evaluation of the royalties to which Dr.
Zandman would be entitled were his employment to be terminated. Based in part
upon the work of this consultant and its own updated computations, management
estimated that the present value of the royalties to which Dr. Zandman would be
entitled were his employment terminated at December 31, 2008 would be between
approximately $370 million and $445 million, with a possible tax gross-up if the
royalties were payable in connection with a change of control and deemed subject
to an excise tax. (This present value does not factor in any assessment of the
probability of payment.)
In December 2008, Dr.
Zandman approached the Compensation Committee with a proposal to amend and
restate his 2004 employment agreement. The Compensation Committee engaged
PricewaterhouseCoopers LLP and independent legal counsel to assist the Committee
in analyzing, responding to and, if appropriate, negotiating the terms of Dr.
Zandman’s proposal. Specifically, PricewaterhouseCoopers was asked to review and
assess the Company’s valuation, based upon the work of its consultant, of the
potential royalty payment amounts under the 2004 Agreement and to advise the
Committee generally with respect to Dr. Zandman’s compensation
package.
26
After extensive
analysis and negotiation with Dr. Zandman on the terms of his proposal, on May
12, 2009, the Compensation Committee approved modifications to the 2004
employment agreement and recommended its approval to the full board of
directors. The Compensation Committee determined that the modifications were in
the best interests of the Company and its stockholders, because they eliminated
the substantial contingent liability represented by the royalty payments,
including a possible gross up if the royalties became payable in connection with
a change of control and were deemed subject to Section 4999 of the Internal
Revenue Code. The possible consequences of this contingent liability for
potential strategic alternatives available to the Company were deemed of
particular concern during a time of the unprecedented disruption that was being
experienced in the global markets. The modifications to Dr. Zandman’s employment
agreement were not considered and approved, however, in response to any specific
transaction then under consideration by the Company.
The amended and
restated employment agreement was approved by the board upon recommendation of
the Compensation Committee on May 13, 2009 and became effective as of that date.
The modifications to the 2004 employment agreement include the following
principal terms:
- Dr. Zandman’s right to the royalty
payments has been terminated.
- Dr. Zandman is entitled to a payment of
$10 million as of the effective date of the amended and restated agreement,
to be followed by five
successive annual payments of $10 million.
- Payments may be deferred with interest in
the event that making such payment would jeopardize the ability of the
Company to continue as a going
concern.
- Payments will accelerate if, following a
change of control of the Company, Dr. Zandman is terminated without
cause or if he terminates
employment for good reason. In the event of Dr. Zandman’s death or disability,
the unpaid annual installments would accelerate upon a change of control,
whether it occurs before or after the death or disability. If an excise tax
were imposed under Section 4999 of the Internal Revenue Code due to the
acceleration of the payments, the Company will reimburse Dr. Zandman for the
excise tax on customary terms.
- Absent a change of control, if the
Company were to terminate Dr. Zandman’s employment without cause or Dr.
Zandman were to terminate
employment for good reason or in the event of his death or disability, the
unpaid annual installment payments would not accelerate and would continue
until completed.
- Dr. Zandman will forfeit future payments
if he terminates his employment without good reason or if his employment is terminated for
cause.
- Dr. Zandman will not receive any other
severance payments upon his termination of employment for any
reason.
- Other terms of the 2004 Agreement remain
substantially the same. Dr. Zandman continues to be subject to
non-competition,
non-solicitation, non-disparagement and confidentiality covenants.
A copy of Dr.
Zandman’s amended employment agreement was filed as an exhibit to the Company’s
Current Report on Form 8-K/A filed with the Securities and Exchange Commission
on May 15, 2009.
Retirement benefits
The Compensation
Committee believes that providing adequate postretirement benefits commensurate
with position is essential to retaining qualified individuals for long-term
employment. Vishay maintains pension programs for most employees in the United
States and Germany, including its executive officers. All pension benefits were
frozen as of January 1, 2009. To mitigate the loss in benefits of these
employees, effective January 1, 2009, we increased the company match portion of
our 401(k) defined contribution savings plan for employees impacted by the
pension freeze. With the exception of Dr. Zandman’s pension, the retirement
benefits for executive officers are not materially preferential to those of
other employees.
27
Perquisites
We provide executive
officers with perquisites and other personal benefits that Vishay and the
Compensation Committee believe are reasonable and consistent with our overall
compensation program. These perquisites are not intended, however, to constitute
a material portion of the executive’s compensation packages. In general, the
perquisites, while not integral to the performance of an executive’s duties,
must bear some relationship to the executive’s employment and be of perceived
benefit to Vishay. The Compensation Committee periodically reviews the levels of
perquisites and other personal benefits provided to named executive
officers.
Individual considerations
The disparity in
compensation among the Company’s senior executives reflects a general assessment
of their contributions to the Company’s current performance and its prospects
for growth in the future. While Dr. Zandman no longer serves as Chief Executive
Officer, he continues to function as Chief Technical Officer and Chief Business
Development Officer. The Company’s successes have always been driven by the twin
engines of technological innovation and synergistic acquisition. Dr. Zandman
continues to lead in both these areas and his higher compensation reflects a
perception by the Compensation Committee that the areas of his responsibility
will continue to be the key drivers for the Company’s future performance. The
compensation of Dr. Paul is intended to be commensurate with his responsibility
and oversight, as President and Chief Executive Officer, for all areas of the
Company’s operations. While it is anticipated that Mr. Marc Zandman will succeed
to the Company's top operational post over time, he is currently responsible
primarily for specific areas of the Company's operations and reports to the
Chief Executive Officer. The relatively lower compensation for Mr. Marc Zandman
reflects his current transitional status. Mr. Shoshani relinquished his position
as Chief Operating Officer on November 1, 2009 to become Executive Vice
President of the Vishay Precision Group. Mr. Shoshani is expected to serve as
Chief Executive Officer and President, and serve on the Board of Directors of
Vishay Precision Group if the intended spin-off is completed. He will resign his
executive positions with our Company, but is expected to remain on Vishay
Intertechnology’s Board of Directors. He will resume his position as COO of
Vishay if the intended spin-off does not take place.
Dr. Lior Yahalomi’s Employment
Arrangements
As noted above, Dr.
Yahalomi’s employment arrangements were negotiated in the fall of 2008 and are
qualitatively different in several respects than the arrangements negotiated in
2004 with the other senior executive officers. The differences are reflective of
Dr. Yahalomi’s limited tenure with the Company to date.
Under his contract,
Dr. Yahalomi receives a base salary of $362,500 per year. Dr. Yahalomi is
entitled to receive a discretionary bonus of up to 50% of base salary as
determined by the Compensation Committee or the Chief Executive
Officer.
The terms of Dr.
Yahalomi’s severance arrangements are described elsewhere in this proxy
statement, but are limited to a maximum of 12 months of base
salary.
Dr. Yahalomi is
entitled to participate in any and all medical insurance, group health
insurance, disability insurance, life insurance and retirement plans which are
generally made available by the Company to its senior executives, subject to
plan requirements. However, he does not receive Company contributions under the
Company’s nonqualified deferred compensation plan and does not participate in
the Senior Executive Phantom Stock Plan.
On March 18, 2010,
the Compensation Committee and the Board of Directors approved certain changes
in the employment arrangements of the named executive officers effective for
2010. A summary of the changes can be found following the 2009 executive
compensation section below.
28
2009 Executive Compensation
The components of
2009 compensation for Drs. Zandman and Paul and Messrs. Marc Zandman and
Shoshani were largely consistent with their employment agreements and consisted
of:
- base salary;
- cash and equity performance-based
bonuses;
- deferred
compensation;
- other equity
compensation;
- severance or change in control
benefits;
- retirement benefits;
and
- perquisites and other personal
benefits.
In addition, Messrs.
Marc Zandman and Shoshani were awarded extra-contractual Restricted Stock Units
(“RSUs”) under the Company’s 2007 Stock Incentive Program. Messrs. Marc Zandman
and Shoshani were eligible to receive RSU grants in 2008, however, the Company
had to make certain regulatory filings in Israel before such grants could be
made to these executives. These approvals were received in 2009.
The components of
2009 compensation for Dr. Yahalomi, based on his formal employment agreement,
consisted of:
- base salary; and
- perquisites and other personal
benefits.
The tables and
accompanying footnotes that follow provide additional information regarding the
compensation earned, held by, or paid to each of our named executive officers in
2009.
Base salary
Base salaries for
2009 are set forth below:
|
|
|
|
Percentage Increase
from |
Name |
|
2009 Base Salary |
|
Prior Year(1) |
Dr. Felix Zandman |
|
$975,000 |
|
None |
Dr. Gerald Paul |
|
€752,776 (approximately $1,045,000)(2) |
|
None |
Dr. Lior Yahalomi |
|
$362,500 |
|
None |
Marc Zandman |
|
NIS 1,422,981 (approximately $362,000)(3) |
|
None |
Ziv Shoshani |
|
NIS 1,201,329 (approximately
$305,000)(3) |
|
None |
____________________
(1) |
|
Determined in the currency of payment |
|
(2) |
|
Paid
in Euro. |
|
(3) |
|
Paid
in Israeli shekels (NIS). |
As noted above, the
base salaries of the senior executive officers were not increased in 2009.
29
Performance-based bonus
Drs. Zandman and Paul
are entitled to receive bonuses in accordance with the 162(m) Plan, while Dr.
Yahalomi along with Messrs. Marc Zandman and Shoshani receive performance
bonuses, in accordance with the terms of their respective contracts. The bonuses
for Drs. Zandman and Paul are limited to three times base salary by the terms of
the 162(m) Plan. The bonuses for Dr. Yahalomi and Messrs. Marc Zandman and
Shoshani are limited to 50%, 42.5%, and 42.5% of their respective base
salaries.
Due to the
unprecedented global recession experienced in 2009, no performance-based bonuses
were awarded to Dr. Yahalomi and Messrs. Marc Zandman and Shoshani. At their
discretion, Drs. Zandman and Paul decided to forego the cash bonuses to which
they were entitled.
Stock-based compensation
In 2009, the
Compensation Committee awarded 10,000 RSUs to Messrs. Marc Zandman and Shoshani
who were eligible to receive these grants in 2008 based on the Company’s 2007
performance. Certain regulatory filings prevented the approval of these grants
until 2009. For Messrs. Marc Zandman and Shoshani, the RSUs vest in six equal
installments, the first on the date of the grant (April 23, 2009), the second on
May 28, 2009, and the remainder on the first four anniversaries of that
date.
Other Considerations Regarding Executive
Compensation
Israeli benefits
Mr. Marc Zandman and
Mr. Shoshani are employed by Vishay Israel Ltd., an Israeli subsidiary of Vishay
Intertechnology, Inc. and are residents of Israel. As a result, they are
entitled to certain benefits that are generally available to employees in Israel
on a non-discriminatory basis, but are not afforded to the other named executive
officers, including:
- advanced training fund, 7.5% of
base salary
- severance fund, 8.33% of base
salary
- disability insurance, 2.5% of base
salary
- pension fund, 5% of base salary
These benefits are
required by Israeli law or employment practices generally, and were taken into
account by the Compensation Committee in formulating the overall compensation
package for these executives.
Foreign currency considerations
Dr. Paul is employed
by Vishay Europe GmbH, a German subsidiary of Vishay Intertechnology, Inc., and
is a German citizen. Accordingly, our employment agreement with Dr. Paul
provides for his base salary to be denominated (and paid) in euro. Messrs. Marc
Zandman and Shoshani, as residents of Israel, have their base salaries
denominated (and paid) in new Israeli shekels. With the weakening of the U.S.
dollar versus the euro and the Israeli shekel in recent years, the amounts
reported in U.S. dollars as compensation for these executives effectively
increased. The Compensation Committee evaluates the effect of foreign currency
conversion rates in formulating the overall compensation package for these
executives.
30
Tax deductibility of executive compensation
Section 162(m) of the
Internal Revenue Code limits to $1 million the annual tax deduction for
compensation paid to each of the Chief Executive Officer and any of the three
highest paid other executive officers, other than the Chief Executive Officer
and the Chief Financial Officer. However, compensation that qualifies as
performance-based compensation is deductible even in excess of $1 million. As
part of its role, the Compensation Committee reviews and considers the
deductibility of executive compensation under Section 162(m) of the Code. Vishay
believes that the compensation generally is fully deductible for federal income
tax purposes. The annual bonuses under the 162(m) Plan are based on Vishay’s
earnings, and therefore qualify as performance-based compensation. All stock
options awarded by Vishay also qualify as performance-based compensation, as do
most awards of restricted stock and restricted stock units, the vesting of which
requires the Company to achieve performance targets of a type contemplated by a
plan approved by stockholders.
In certain
situations, the Compensation Committee may approve compensation that will not
satisfy the requirements of Section 162(m), in order to ensure competitive
levels of total compensation for its executive officers. For example, Dr. Paul’s
base salary for 2009 exceeded $1 million, largely because his salary is payable
in euro and the dollar has weakened considerably against the euro in recent
years. The 2004 employment agreements provide for mandatory deferral of any such
compensation under those agreements until the payment of the compensation would
be deductible by Vishay for federal income tax purposes. The restricted stock
units granted in 2009 do not qualify as performance-based compensation. The
Compensation Committee determined that the factors favoring granting these
awards outweighed the tax considerations.
Certain covenants
Under the terms of
their employment contracts, the executives are subject to customary
non-competition, non-solicitation, non-disparagement and confidentiality
covenants. The non-competition and non-solicitation covenants for executives
other than Dr. Zandman remain in force through the second anniversary of the
date of termination of the executive’s employment with the Company. The
covenants for Dr. Zandman are intended to continue in force for the longest
period allowed by law. The non-disparagement and confidentiality covenants have
no specified term. While the payments and benefits to the executives are made in
consideration of the executives’ compliance with these covenants, there are no
specific forfeiture provisions in the employment contracts for a breach of the
covenants.
REPORT OF THE COMPENSATION COMMITTEE
To Our Stockholders:
We have reviewed and
discussed with management the Compensation Discussion and Analysis. Based on
that review and discussion, we have recommended to the Board of Directors that
the Compensation Discussion and Analysis be included in this proxy statement.
Respectfully
submitted,
The Compensation
Committee of the Board of Directors
Wayne Rogers,
Chairman
Zvi Grinfas
Dr. Abraham Ludomirski
Thomas C. Wertheimer
31
COMPENSATION TABLES
Summary Compensation Table
The following table summarizes information regarding compensation earned, held by, or paid to our named
executive officers during 2009. The
information included in the table
should be read in conjunction with the
footnotes which follow, the descriptions of the employment agreements with each named
executive officer described in “Compensation Discussion and Analysis,” and the
“Grants of Plan Based Awards,” “Outstanding Equity
Awards,” “Option Exercises and Stock Vested,” “Pension Benefits,” and “Nonqualified Deferred Compensation” tables on
the pages which follow:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-Equity |
|
Non-qualified |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options |
|
Incentive |
|
Deferred Comp. |
|
All Other |
|
|
|
|
|
|
Salary |
|
Bonus |
|
Stock Awards |
|
Awards |
|
Plan Comp. |
|
Earnings |
|
Comp. |
|
|
|
|
|
|
(1) |
|
(2) |
|
(3) |
|
(4) |
|
(2) |
|
(5) (6) |
|
(7) |
|
Total |
Name and Principal
Position |
|
Year |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
(a) |
|
(b) |
|
(c) |
|
(d) |
|
(e) |
|
(f) |
|
(g) |
|
(h) |
|
(i) |
|
(j) |
Dr. Felix Zandman |
|
2009 |
|
$ |
975,000 |
|
$10,000,000 |
|
$ |
18,500 |
|
— |
|
|
— |
|
$ |
656,622 |
|
$ |
234,844 |
|
$ |
11,884,966 |
Executive Chairman of the Board
and |
|
2008 |
|
|
975,000 |
|
— |
|
|
887,020 |
|
— |
|
$ |
2,925,000 |
|
|
— |
|
|
199,607 |
|
|
4,986,627 |
Chief Technical and Business |
|
2007 |
|
|
975,000 |
|
— |
|
|
68,750 |
|
3,780,000 |
|
|
2,925,000 |
|
|
— |
|
|
196,452 |
|
|
7,945,202 |
Development Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Gerald Paul |
|
2009 |
|
|
1,044,615 |
|
— |
|
|
18,500 |
|
— |
|
|
— |
|
|
102,901 |
|
|
137,500 |
|
|
1,303,516 |
President and Chief Executive
Officer |
|
2008 |
|
|
1,103,939 |
|
— |
|
|
610,380 |
|
— |
|
|
991,889 |
|
|
163,548 |
|
|
137,500 |
|
|
3,007,256 |
|
|
2007 |
|
|
961,105 |
|
— |
|
|
68,750 |
|
2,520,000 |
|
|
1,814,948 |
|
|
214,651 |
|
|
137,500 |
|
|
5,716,954 |
|
Dr. Lior Yahalomi |
|
2009 |
|
|
362,650 |
|
— |
|
|
— |
|
— |
|
|
— |
|
|
17,464 |
|
|
31,998 |
|
|
412,112 |
Executive Vice President and
Chief |
|
2008 |
|
|
295,144 |
|
— |
|
|
— |
|
261,600 |
|
|
45,313 |
|
|
19,048 |
|
|
14,156 |
|
|
635,261 |
Financial Officer (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marc Zandman |
|
2009 |
|
|
361,694 |
|
— |
|
|
69,700 |
|
— |
|
|
— |
|
|
13,403 |
|
|
258,841 |
|
|
703,638 |
Vice Chairman of the Board,
Chief |
|
2008 |
|
|
396,594 |
|
— |
|
|
57,100 |
|
— |
|
|
90,225 |
|
|
5,323 |
|
|
303,162 |
|
|
852,404 |
Administration Officer, and President
- |
|
2007 |
|
|
333,704 |
|
— |
|
|
68,750 |
|
356,250 |
|
|
101,780 |
|
|
— |
|
|
219,385 |
|
|
1,079,869 |
Vishay Israel Ltd. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ziv Shoshani |
|
2009 |
|
|
305,359 |
|
— |
|
|
69,700 |
|
— |
|
|
— |
|
|
8,957 |
|
|
222,385 |
|
|
606,401 |
Executive Vice President - |
|
2008 |
|
|
334,819 |
|
— |
|
|
57,100 |
|
— |
|
|
39,341 |
|
|
3,664 |
|
|
297,824 |
|
|
732,748 |
Vishay Precision Group, and Director
(9) |
|
2007 |
|
|
281,724 |
|
— |
|
|
68,750 |
|
356,250 |
|
|
69,586 |
|
|
— |
|
|
206,563 |
|
|
982,873 |
32
(1) |
|
Column
(c) reflects base salary earned during the respective years and, for Drs.
Zandman and Paul, includes amounts deferred in accordance with the
provisions of our 401(k) plan. Dr. Paul’s employment agreement specifies
that his salary be denominated and paid in euro. The employment agreements
for Messrs. Marc Zandman and Shoshani provide for their salaries to be
denominated in U.S. dollars, but the Company subsequently agreed with the
executives to denominate their salaries in Israeli shekels. The amounts
presented above have been converted into U.S. dollars at the weighted
average exchange rate for the year. |
|
(2) |
|
Due to
the unprecedented global recession experienced in 2009, no
performance-based bonuses were awarded to Dr. Yahalomi and Messrs. Marc
Zandman and Shoshani. At their discretion, Drs. Zandman and Paul decided
to forego the cash bonuses to which they were entitled. Column (d)
reflects cash paid to Dr. Zandman in 2009 related to his amended and
restated employment agreement described on pages 26 and 27. |
|
(3) |
|
Column
(e) represents the grant-date fair value of 5,000 phantom stock units
awarded annually to certain named executive officers pursuant to the terms
of their employment agreements. The common stock underlying these awards
is not received until termination of employment, and accordingly, there
can be no assurance that the grant-date fair value of these awards will
ever be realized. Column (e) also includes the grant-date fair value of
restricted stock units granted in that year. The grant-date fair value is
recognized for accounting purposes over the vesting periods of the
respective awards. No amounts are included for performance based
restricted stock units. |
|
(4) |
|
Column
(f) represents the grant-date fair value of stock options granted to the
named executive officers during 2007, 2008, and 2009. The grant-date fair
value is recognized over the vesting periods of the respective awards.
There can be no assurance that the grant-date fair value of these awards
will ever be realized. The assumptions used in computing the grant-date
fair value are detailed in Note 12 to Vishay’s consolidated financial
statements for the year ended December 31, 2009, included in its Annual
Report on Form 10-K. No stock options were exercised in 2009. |
|
(5) |
|
Column
(h) reflects the change in the actuarial present value of the named
executive officer’s pension and other post employment benefits under
respective defined benefit retirement plans, from the plan measurement
date used in preparing the prior year consolidated financial statements to
the plan measurement date used in preparing the current year consolidated
financial statements, determined using the same interest rate, mortality,
and other actuarial assumptions used in our consolidated financial
statements. For Dr. Paul, conversion of his euro-denominated pension
benefit into U.S. dollars had the impact of increasing the amount
disclosed by $210,000 in 2007, $146,000 in 2008, and $ 76,000 in 2009.
Column (h) does not include any amounts for the benefits payable to Dr.
Zandman for 2007 and 2008 because changes in actuarial assumptions reduced
the present value of Dr. Zandman’s accumulated benefit by $405,000 at
December 31, 2007 compared to December 31, 2006 and by $199,507 at
December 31, 2008 compared to December 31, 2007. See the “Pension
Benefits” table for more information on the benefits payable to the named
executive officers under their respective pension plans. |
|
(6) |
|
The
named executive officers (with the exception of Dr. Yahalomi) also
participate in our nonqualified deferred compensation plan under which
amounts deferred are credited with earnings based on the performance of
notional investment options available under the plan. No portion of the
earnings credited during 2007, 2008, or 2009 was “above market” or
“preferential.” Consequently, no deferred compensation plan earnings are
included in the amounts reported in Column (h). See the “Nonqualified
Deferred Compensation” table for more information on the benefits payable
under the nonqualified deferred compensation plan. |
|
(7) |
|
All
other compensation includes amounts deposited on behalf of each named
executive officer into Vishay’s nonqualified deferred compensation plan
pursuant to the employment agreements with each named executive officer,
personal use of company car, Company match on 401(k) contributions,
benefits generally available to employees in Israel, and other
perquisites, as described below (asterisk denotes amounts paid in foreign
currency and translated at average exchange rates for the
year): |
33
|
|
2009 |
|
2008 |
|
2007 |
|
|
Dr. Felix Zandman |
|
$ |
147,735 |
|
$ |
147,735 |
|
$ |
150,000 |
|
Company contribution to non-qualified
deferred compensation plan |
|
|
|
22,200 |
|
|
22,200 |
|
|
22,200 |
|
Personal use of Company car |
|
|
|
9,800 |
|
|
4,600 |
|
|
4,500 |
|
Company match to 401(k)
plan |
|
|
|
43,985 |
|
|
13,948 |
|
|
8,628 |
|
Company-paid medical costs |
|
|
|
11,124 |
|
|
11,124 |
|
|
11,124 |
|
Group Term Life imputed
income |
|
Dr. Gerald Paul |
|
$ |
100,000 |
|
$ |
100,000 |
|
$ |
100,000 |
|
Company contribution to non-qualified
deferred compensation plan |
|
|
|
37,500 |
|
|
37,500 |
|
|
37,500 |
|
Personal use of Company
car* |
|
Dr. Lior Yahalomi |
|
$ |
9,800 |
|
$ |
859 |
|
$ |
- |
|
Company contribution to non-qualified
deferred compensation plan |
|
|
|
11,881 |
|
|
7,455 |
|
|
- |
|
Personal use of Company car |
|
|
|
9,075 |
|
|
4,600 |
|
|
- |
|
Company match to 401(k)
plan |
|
|
|
1,242 |
|
|
1,242 |
|
|
- |
|
Group Term Life imputed
income |
|
Marc Zandman |
|
$ |
100,000 |
|
$ |
100,000 |
|
$ |
100,000 |
|
Company contribution to non-qualified
deferred compensation plan |
|
|
|
17,478 |
|
|
16,158 |
|
|
9,288 |
|
Personal use of Company
car* |
|
|
|
114,316 |
|
|
159,957 |
|
|
83,963 |
|
Israeli employment
benefits* |
|
|
|
27,047 |
|
|
27,047 |
|
|
26,134 |
|
Medical and prescription drug insurance
premiums (Blue Cross / Blue Shield) |
|
Ziv Shoshani |
|
$ |
100,000 |
|
$ |
100,000 |
|
$ |
100,000 |
|
Company contribution to non-qualified
deferred compensation plan |
|
|
|
15,638 |
|
|
12,871 |
|
|
9,537 |
|
Personal use of Company
car* |
|
|
|
79,700 |
|
|
157,906 |
|
|
70,892 |
|
Israeli employment
benefits* |
|
|
|
27,047 |
|
|
27,047 |
|
|
26,134 |
|
Medical and prescription drug insurance
premiums (Blue Cross / Blue
Shield) |
____________________
(8) |
|
Dr. Yahalomi was
appointed Executive Vice President and Chief Financial Officer on
September 1, 2008. Amounts presented for 2008 include amounts earned in
his previous position as Senior Vice President - Mergers and
Acquisitions. |
|
(9) |
|
Mr. Shoshani was
appointed Chief Operating Officer effective January 1, 2007 and resigned
this position on November 1, 2009. He is now Executive Vice President –
Vishay Precision Group, and is expected to serve as the President and
Chief Executive Officer, and will also serve on the Board of Directors of
Vishay Precision Group if the intended spin-off of our foil resistors and
measurements businesses into an independent, publicly-traded company is
completed. He will also resign his executive positions with Vishay
Intertechnology, Inc., but retain his membership on our board of
directors. If the intended spin-off does not take place, Mr. Shoshani will
resume his previous position as Chief Operating Officer of Vishay
Intertechnology, Inc. |
34
Grants of Plan Based Awards
The following table
provides information with regard to plan based awards granted to each named
executive officer during 2009. The information included in the table should be
read in conjunction with the footnotes which follows and the description of
Vishay’s Senior Executive Phantom Stock Plan described in “Compensation
Discussion and Analysis.”
|
|
|
|
|
|
All
Other |
|
|
|
|
|
|
|
|
|
|
|
|
Stock |
|
|
|
|
|
|
|
|
|
|
Estimated
Future |
|
Awards: |
|
All
Other |
|
|
|
|
|
|
|
|
Payouts Under |
|
Number of |
|
Option Awards: |
|
|
|
Grant Date Fair |
|
|
|
|
Non-Equity |
|
Shares of |
|
Number of |
|
|
|
Value of Stock |
|
|
|
|
Incentive Plan |
|
Stock or |
|
Securities |
|
Exercise or Base |
|
and Option |
|
|
|
|
Awards Max |
|
Units |
|
Underlying |
|
Price of Option |
|
Awards |
|
|
|
|
($) |
|
(#) |
|
Option |
|
Awards |
|
($) |
Name |
|
Grant Date |
|
(1) |
|
(2) |
|
(#) |
|
($/sh) |
|
(3) |
Dr. Felix Zandman |
|
1/2/2009 |
|
$ |
2,925,000 |
|
5,000 |
|
— |
|
— |
|
$ |
18,500 |
|
Dr. Gerald Paul |
|
1/2/2009 |
|
$ |
3,134,000 |
|
5,000 |
|
— |
|
— |
|
$ |
18,500 |
|
Marc Zandman |
|
1/2/2009 |
|
$ |
— |
|
5,000 |
|
— |
|
— |
|
$ |
18,500 |
|
|
4/23/2009 |
|
|
— |
|
10,000 |
|
— |
|
— |
|
|
51,200 |
|
Ziv Shoshani |
|
1/2/2009 |
|
$ |
— |
|
5,000 |
|
— |
|
— |
|
$ |
18,500 |
|
|
4/23/2009 |
|
|
— |
|
10,000 |
|
— |
|
— |
|
|
51,200
|
____________________
(1) |
|
Amounts in this column represent three times the executive’s base
salary in the case of each of Drs. Zandman and Paul, because their maximum
bonuses are limited under the Company’s 162(m) Plan to such amount. Drs.
Zandman and Paul would have been entitled to bonuses of $97,757 and
$32,586, respectively, pursuant to their employment agreements, however at
their discretion, Drs. Zandman and Paul decided to forego their cash
bonuses for 2009. Due to the unprecedented global recession experienced in
2009, no performance-based bonuses were awarded to Dr. Yahalomi and
Messrs. Marc Zandman and Shoshani. |
|
(2) |
|
Included in this column are awards of phantom stock granted
effective January 2, 2009, and awards of restricted stock units granted to
Messrs. Shoshani and Marc Zandman related to 2007 performance that could
not be awarded until 2009. The RSU grants are effective April 23,
2009. |
|
(3) |
|
Amounts in this column include: |
|
|
|
|
|
- the grant-date fair value of 5,000 phantom stock units awarded
annually to certain executive officers pursuant to the terms of their
employment agreements. The amount is calculated using the closing price
of Vishay stock on the grant date of $3.70. The common stock underlying
these awards is not received until termination of employment, and
accordingly, there can be no assurance that the grant-date fair value of
these awards will ever be realized;
- the grant-date fair value of the restricted stock units. The amount
is calculated using the closing price of Vishay stock on the date of
grant of $5.12. The common stock underlying these awards is not received
until the awards are vested, and accordingly, there can be no assurance
that the grant-date fair value of these awards will ever be realized.
|
35
Outstanding Equity Awards at Fiscal Year End
The following table
provides information regarding unexercised stock options held by our named
executive officers as of December 31, 2009.
|
|
Option Awards |
|
Stock Awards |
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan Awards: |
|
|
|
|
|
|
|
|
|
|
|
|
Number of |
|
Number of |
|
Number of |
|
|
|
|
|
Number of |
|
Market Value |
|
|
|
|
Securities |
|
Securities |
|
Securities |
|
|
|
|
|
Shares or |
|
of Shares or |
|
|
|
|
Underlying |
|
Underlying |
|
Underlying |
|
|
|
|
|
Units of |
|
Units of |
|
|
|
|
Unexercised |
|
Unexercised |
|
Unexercised |
|
Option |
|
Option |
|
Stock That |
|
Stock That |
|
|
Grant |
|
Options (#) |
|
Options (#) |
|
Unearned |
|
Exercise |
|
Expiration |
|
Have Not |
|
Have Not |
Name |
|
Date (1) |
|
Exercisable |
|
Unexercisable |
|
Options (#) |
|
Price ($) |
|
Date |
|
Vested (#) |
|
Vested ($) |
Dr. Felix Zandman |
|
10/12/2000 |
|
27,000 |
|
— |
|
— |
|
$ |
25.13 |
|
10/12/2010 |
|
— |
|
|
— |
|
|
5/22/2007 |
|
70,000 |
|
140,000 |
|
— |
|
$ |
18.00 |
|
5/22/2017 |
|
— |
|
|
— |
|
|
5/28/2008 |
|
— |
|
— |
|
— |
|
|
— |
|
— |
|
56,000 |
|
$ |
467,600 |
Total |
|
|
|
97,000 |
|
140,000 |
|
— |
|
|
|
|
|
|
56,000 |
|
$ |
467,600 |
|
Dr. Gerald Paul |
|
10/12/2000 |
|
18,000 |
|
— |
|
— |
|
$ |
25.13 |
|
10/12/2010 |
|
— |
|
|
— |
|
|
5/22/2007 |
|
46,668 |
|
93,332 |
|
— |
|
$ |
18.00 |
|
5/22/2017 |
|
— |
|
|
— |
|
|
5/28/2008 |
|
— |
|
— |
|
— |
|
|
— |
|
— |
|
37,334 |
|
$ |
311,739 |
Total |
|
|
|
64,668 |
|
93,332 |
|
— |
|
|
|
|
|
|
37,334 |
|
$ |
311,739 |
|
Dr. Lior Yahalomi |
|
6/26/2006 |
|
10,001 |
|
9,999 |
|
— |
|
$ |
15.83 |
|
6/26/2016 |
|
— |
|
|
— |
|
|
6/26/2007 |
|
8,334 |
|
16,666 |
|
— |
|
$ |
15.61 |
|
6/26/2017 |
|
— |
|
|
— |
|
|
8/18/2008 |
|
5,000 |
|
25,000 |
|
— |
|
$ |
8.72 |
|
8/18/2018 |
|
— |
|
|
— |
Total |
|
|
|
23,335 |
|
51,665 |
|
— |
|
|
|
|
|
|
— |
|
|
— |
|
Marc Zandman |
|
10/12/2000 |
|
12,000 |
|
— |
|
— |
|
$ |
25.13 |
|
10/12/2010 |
|
— |
|
|
— |
|
|
2/27/2007 |
|
8,334 |
|
16,666 |
|
— |
|
$ |
14.25 |
|
2/27/2017 |
|
— |
|
|
— |
|
|
4/23/2009 |
|
— |
|
— |
|
— |
|
|
— |
|
— |
|
6,668 |
|
|
55,678 |
Total |
|
|
|
20,334 |
|
16,666 |
|
— |
|
|
|
|
|
|
6,668 |
|
|
55,678 |
|
Ziv Shoshani |
|
10/12/2000 |
|
12,000 |
|
— |
|
— |
|
$ |
25.13 |
|
10/12/2010 |
|
— |
|
|
— |
|
|
2/27/2007 |
|
8,334 |
|
16,666 |
|
— |
|
$ |
14.25 |
|
2/27/2017 |
|
— |
|
|
— |
|
|
4/23/2009 |
|
— |
|
— |
|
— |
|
|
— |
|
— |
|
6,668 |
|
|
55,678 |
Total |
|
|
|
20,334 |
|
16,666 |
|
— |
|
|
|
|
|
|
6,668 |
|
|
55,678 |
____________________
(1) |
|
Options vest in six equal annual installments beginning on the
first anniversary of the date of grant. |
36
Option Exercises and Stock
Vested
The following table
provides information with regard to amounts paid to or received by our named
executive officers during 2009 as a result of the exercise of stock options and
vesting of restricted stock units.
|
|
Option Awards |
|
Stock Awards |
|
|
Number of |
|
|
|
|
Number of |
|
|
|
|
|
Shares |
|
Value |
|
Shares |
|
Value |
|
|
Acquired |
|
Realized on |
|
Acquired |
|
Realized on |
|
|
on Exercise |
|
Exercise |
|
on Vesting |
|
Vesting |
Name |
|
(#) |
|
($) |
|
(#) |
|
($) |
(a) |
|
(b) |
|
(c) |
|
(d) |
|
(e) |
Dr. Felix Zandman |
|
— |
|
$ |
— |
|
14,000 |
|
$ |
77,000 |
Dr. Gerald Paul |
|
— |
|
|
— |
|
9,333 |
|
|
51,332 |
Mr. Ziv Shoshani |
|
— |
|
|
— |
|
3,332 |
|
|
17,693 |
Mr. Marc Zandman |
|
— |
|
|
— |
|
3,332 |
|
|
17,693 |
Pension Benefits
Vishay maintains
various retirement benefit plans and arrangements.
Dr. Zandman’s
employment agreement provides an annual retirement benefit equal to 50% of his
average base pay and bonus for the five years preceding his retirement (but not
to exceed $1 million annually). These benefits are fully vested. Dr. Zandman
does not participate in any of Vishay’s defined benefit retirement
plans.
Vishay Europe GmbH, a
German subsidiary of Vishay, has a noncontributory defined benefit plan governed
by German law covering its management and executive employees. Dr. Paul is the
only named executive officer that participates in this plan. Dr. Paul also has
an individual contractual pension arrangement with Vishay Europe GmbH that will
pay an annual benefit upon retirement at age 65 based on his years of service
(up to 25) and average salary and bonus in the three highest of his final ten
years of employment (“final average compensation”). The retirement benefit will
not exceed 40% of such final average compensation, and the individual
contractual pension amount will be reduced by pension amounts payable under the
Company plan. Dr. Paul has voluntarily agreed to a maximum limit of €180,000 per
year with respect of such final average compensation. The Compensation Committee
may, however, in its sole discretion, elect to increase the €180,000 limitation
to reflect Dr. Paul’s actual salary and bonus, to take into account cost of
living adjustments, or as it may otherwise deem appropriate.
In the United States,
Vishay maintained a pension plan which provided defined benefits to U.S.
employees whose benefits under the qualified pension plan would be limited by
the Employee Retirement Income Security Act of 1974 (“ERISA”) and the Internal
Revenue Code. Effective January 1, 2009, the U.S. pension plans were frozen.
Benefits accumulated as of December 31, 2008 will be paid to employees upon
retirement, but no further benefits will accrue beyond that date. To mitigate
the loss in benefits of these employees, effective January 1, 2009, the Company
increased the Company-match portion of its 401(k) defined contribution savings
plan for employees impacted by the pension freeze. Dr. Yahalomi is the only
executive officer that participates in this defined benefit plan.
The plan was
contributory and, other than the fact that it is nonqualified under ERISA,
provided substantially the same benefits that are available under Vishay’s
qualified retirement plan. Employees with five or more years of service were
entitled to annual pension benefits beginning at normal retirement age on the
first day of the month following the participant’s 65th birthday equal to the
sum of 2.1% of the first $10,000 of earnings plus 2.64% of the annual earnings
in excess of $10,000 with a new pension unit earned each year. The final pension
is the sum of all units earned during the employee’s career. The plan permits
early retirement if the participant is at least age 55 and has at least five
years of service. Employees may elect to receive their pension benefits in the
form of a joint and survivor annuity or other contingent annuities. Employees
are 100% vested immediately in their contributions. If employees terminate
before rendering five years of service, they forfeit the right to receive the
portion of their accumulated plan benefits attributable to the Company's
contributions. Employees receive the value of their accumulated benefits as a
life annuity payable monthly from retirement. For each employee electing a life
annuity, payments will not be less than the greater of (a) the employee’s
accumulated contributions plus interest or (b) an annuity for five
years.
37
As part of their
respective employment agreements, certain executive officers and their surviving
spouses are entitled to receive medical coverage up to a $15,000 annual premium
value for life if they terminate employment after attaining age 62. These
benefits are fully vested.
The following table
provides information regarding the present value of benefits accrued under these
retirement benefit plans and arrangements:
|
|
|
|
Number |
|
Present |
|
|
|
|
|
|
of Years |
|
Value of |
|
Payments |
|
|
|
|
Credited |
|
Accumulated |
|
During Last |
|
|
|
|
Service |
|
Benefit (1) |
|
Fiscal Year |
Name |
|
Plan Name |
|
(#) |
|
($) |
|
($) |
(a) |
|
(b) |
|
(c) |
|
(d) |
|
(e) |
Dr. Felix Zandman |
|
Individual
contractual pension arrangement |
|
n/a |
|
$ |
4,274,488 |
|
— |
|
|
Individual
contractual post-employment medical arrangement |
|
n/a |
|
|
74,858 |
|
— |
|
Dr. Gerald Paul(2) |
|
Vishay Europe GmbH
Pension Plan and individual contractual arrangement |
|
32 |
|
|
1,805,377 |
|
— |
|
|
Individual
contractual post-employment medical arrangement |
|
n/a |
|
|
182,826 |
|
— |
|
Dr. Lior Yahalomi |
|
Vishay
Nonqualified Retirement Plan |
|
2.5 |
|
|
48,987 |
|
— |
|
Marc Zandman |
|
Individual
contractual post-employment medical arrangement |
|
n/a |
|
|
65,307 |
|
— |
|
Ziv Shoshani |
|
Individual
contractual post-employment medical arrangement |
|
n/a |
|
|
36,569 |
|
— |
____________________
(1) |
|
These amounts
have been calculated using interest rate, mortality, and other actuarial
assumptions consistent with those used for financial reporting purposes
set forth in Note 11 to Vishay’s consolidated financial statements
included in our 2009 Annual Report on Form 10-K.
|
|
(2) |
|
Dr. Paul’s
benefits are denominated in Euros. The dollar amount shown in the table is
based on the year to date weighted average conversion rate for
2009.
|
38
Nonqualified Deferred
Compensation
The named executive
officers participate in a nonqualified deferred compensation plan, which is
available to all employees which meet certain criteria under the Internal
Revenue Code. Certain executive officers are entitled under their respective
employment agreements to annual contributions to this plan by Vishay, less
certain applicable taxes. The named executive officers are also eligible to
elect to defer additional amounts of compensation, subject to certain
limitations. Only Dr. Yahalomi has elected to defer additional amounts of
compensation.
Amounts contributed
to these plans prior to January 1, 2005 were deemed deferred until retirement or
termination of employment. Effective January 1, 2005, all employees that
participate in the plan were given the option to choose shorter deferral periods
for all or a portion of their deferred compensation. All of the named executive
officers have elected to defer all amounts of compensation until retirement or
termination of employment, at which time, the amounts would be paid in a lump
sum. To the extent required to avoid tax penalties, the deferred amounts are not
paid until six months after the termination of employment.
While deferred,
amounts are credited with “earnings” based on the performance of notional
investment options available under the plan. No portion of the earnings credited
during 2009 was “above market” or “preferential.”
The following table
sets forth information relating to the activity in the nonqualified deferred
compensation plan accounts of the named executive officers during 2009 and the
aggregate balance of the accounts as of December 31, 2009:
|
|
|
|
|
Registrant |
|
|
|
|
|
|
Aggregate |
|
|
Executive |
|
Contributions in |
|
Aggregate |
|
Aggregate |
|
Balance at |
|
|
Contributions in |
|
Last Fiscal Year |
|
Earnings in Last |
|
Withdrawals/ |
|
Last Fiscal |
|
|
Last Fiscal Year |
|
(1) |
|
Fiscal Year |
|
Distributions |
|
Year End |
Name |
|
($) |
|
($) |
|
($) |
|
($) |
|
($) |
(a) |
|
(b) |
|
(c) |
|
(d) |
|
(e) |
|
(f) |
Dr. Felix Zandman |
|
$ |
— |
|
$ |
147,735 |
|
$ |
410 |
|
— |
|
$ |
983,448 |
Dr. Gerald Paul |
|
|
— |
|
|
100,000 |
|
|
275 |
|
— |
|
|
660,303 |
Dr. Lior Yahalomi |
|
|
18,125 |
|
|
9,800 |
|
|
85,442 |
|
— |
|
|
404,773 |
Marc Zandman |
|
|
— |
|
|
100,000 |
|
|
111,355 |
|
— |
|
|
622,446 |
Ziv Shoshani |
|
|
— |
|
|
100,000 |
|
|
23,310 |
|
— |
|
|
636,957 |
____________________
(1) |
|
These amounts
are included in Column (i) of the “Summary Compensation Table” as a
component of “All Other Compensation.” No portion of the earnings credited
during 2009 was “above market” or “preferential.” Accordingly, no amounts
related to earnings on deferred compensation have been included in the
“Summary Compensation Table.”
|
Potential Payments Upon Termination or a
Change in Control
Our employment
agreements with our named executive officers provide incremental compensation in
the event of termination, as described below. Generally, Vishay does not provide
any severance or other benefits specifically upon a change in control.
Termination of employment also impacts outstanding stock options, restricted
stock units, phantom stock units, and nonqualified deferred compensation
balances.
39
Current Executives other than Dr. Zandman
The executive
employment contracts of Dr. Paul and Messrs. Marc Zandman and Shoshani contain
severance provisions providing generally for 3 years of compensation in the case
of a termination without cause or a voluntary termination by the executive for
“good reason” (as defined in the employment agreement). Specifically, severance
items include:
- salary continuation for three
years, payable over three years;
- 5,000 shares of common stock
annually for three years. Because these shares are granted after termination
of employment, actual shares – rather than phantom stock units – are
granted;
- bonus for the year of
termination;
- $1,500,000 lump sum cash payment.
This payment replaces the annual deferred compensation credits and the annual
bonus for the 3-year severance period;
- lifetime continuation of
executive’s life insurance benefit; and
- continuation of executive’s
medical benefit for a maximum of three years if the termination occurs before
attaining age 62 and lifetime continuation up to $15,000 annual premium value
if the termination occurs after attaining age 62.
The Company is
required to give Dr. Yahalomi three months prior notice of its intention to
terminate his employment without cause. If he remains employed through the end
of the three month period, he will be entitled to receive a severance payment
equal to nine months of base salary. If the Company terminates his employment
without cause and fails to provide him with three months’ notice, or if it
terminates his employment without cause during the notice period, Dr. Yahalomi
will be entitled to a severance payment equal to 12 months of base salary less
any salary paid to Dr. Yahalomi during the shortened notice period. Dr. Yahalomi
will receive accrued benefits under the Vishay Nonqualified Retirement Plan once
his pension benefits are vested. If he leaves the Company prior to vesting, he
is entitled only to the repayment of his contributions plus associated
interest.
In addition, Dr. Paul
will receive payment of his individual contractual pension in the event of a
termination for any reason, as well as accrued benefits under the Vishay Europe
GmbH pension plan.
The following table
sets forth the compensation that would have been received by each of the
Company’s executive officers other than Dr. Zandman had they been terminated as
of December 31, 2009.
|
|
|
|
|
|
|
|
|
|
Lump sum |
|
|
|
|
|
|
|
Non-qualified |
|
|
|
|
|
|
|
|
|
|
termination |
|
|
|
|
Life insurance / |
|
deferred |
|
|
Salary
cont. |
|
Bonus |
|
Stock
grants |
|
payment |
|
Pension |
|
Medical
benefit |
|
compensation |
|
|
(1) |
|
(2) |
|
(3) |
|
|
|
|
(4) |
|
(4) |
|
(5) |
Dr. Gerald Paul |
|
$ |
3,134,000 |
|
— |
|
$ |
125,250 |
|
$ |
1,500,000 |
|
$ |
1,805,377 |
|
$ |
182,826 |
|
$ |
660,303 |
Dr. Lior Yahalomi |
|
|
362,500 |
|
— |
|
|
— |
|
|
— |
|
|
48,987 |
|
|
— |
|
|
404,773 |
Marc Zandman |
|
|
1,085,081 |
|
— |
|
|
125,250 |
|
|
1,500,000 |
|
|
— |
|
|
65,307 |
|
|
622,446 |
Ziv Shoshani |
|
|
916,077 |
|
— |
|
|
125,250 |
|
|
1,500,000 |
|
|
— |
|
|
36,569 |
|
|
636,957 |
____________________
(1) |
|
Equals 3 times
U.S. dollar value of 2009 salary, paid over three years, for Dr. Paul and
Messrs. Marc Zandman and Shoshani. Equals 12 months of his 2009 salary for
Dr. Yahalomi.
|
|
|
|
(2) |
|
Consists of
bonus and non-equity incentive plan compensation for 2009 as reflected in
the "Summary Compensation Table".
|
|
|
|
(3) |
|
Equals 15,000
shares, multiplied by $8.35, which was the closing price of Vishay’s
common stock on December 31, 2009. The shares are to be paid out over
three years.
|
|
|
|
(4) |
|
Present value
of accumulated benefit reflected in the "Pension Benefits" table, paid
annually until death.
|
|
|
|
(5) |
|
Aggregate
balance at year end as reflected in the "Nonqualified Deferred
Compensation" table.
|
40
Dr. Zandman
On May 13, 2009, the
Company entered into an amended and restated employment agreement with Dr. Felix
Zandman (the “2009 Agreement”).
The purpose of the
2009 Agreement was to eliminate the right of Dr. Zandman to receive a royalty
during the ten years following his termination of employment equal to 5% of
gross sales, less returns and allowances, of Vishay products incorporating
inventions and any other form of technology created, discovered or developed by
him or under his direction. The royalty was payable in the event Dr. Zandman was
terminated without “cause” or resigned for “good reason,” as defined in the 2004
Agreement.
Pursuant to the 2009
Agreement, Dr. Zandman’s right to the royalty payments has been terminated. Dr.
Zandman received a payment of $10 million as of the effective date of the
amended and restated agreement, and is entitled to receive five additional
annual payments of $10 million each.
Payments pursuant to
the 2009 Agreement may be deferred with interest in the event that making such
payment would jeopardize the ability of the Company to continue as a going
concern. Payments will accelerate if, following a change of control of the
Company, Dr. Zandman is terminated without cause or if he terminates employment
for good reason. In the event of Dr. Zandman’s death or disability, the unpaid
annual installments would accelerate upon a change of control, whether it occurs
before or after the death or disability. If an excise tax were imposed under
Section 4999 of the Internal Revenue Code due to the acceleration of the
payments, the Company will reimburse Dr. Zandman for the excise tax on customary
terms. Absent a change of control, if the Company were to terminate Dr.
Zandman’s employment without cause or Dr. Zandman were to terminate employment
for good reason or in the event of his death or disability, the unpaid annual
installment payments would not accelerate and would continue until completed.
Dr. Zandman will forfeit future payments if he terminates his employment without
good reason or if his employment is terminated for cause. Furthermore, as a
result of the 2009 Agreement, Dr. Zandman will not receive any other severance
payments upon his termination of employment for any reason. Other terms of the
2004 Agreement remain substantially the same. Dr. Zandman continues to be
subject to non-competition, non-solicitation, non-disparagement and
confidentiality covenants.
Golden Parachute Gross-up
Section 4999 of the
Internal Revenue Code imposes a 20% excise tax on certain compensation paid upon
a change in control if the compensation exceeds three times the executive’s
average annual compensation. Vishay does not provide any severance or other
benefits specifically upon a change in control, but under the Internal Revenue
Service interpretations of the Section 4999 rules, if a termination of
employment occurred in connection with a change in control, the severance might
be subject to the excise tax. The 2004 employment agreements provide for Vishay
to reimburse the named executive officers for any excise tax. The Compensation
Committee believes that it would be unfair for the executive to be taxed in such
a case since the payments are not intended to be made with respect to a change
in control.
Impact on Nonqualified Deferred Compensation
Balances
As described above,
the named executive officers participate in a nonqualified deferred compensation
plan. All of the named executive officers have elected to defer such
compensation until retirement or termination of employment, at which time the
amounts would be paid in a lump sum.
41
Impact on Outstanding Stock Options
The named executive
officers have stock options outstanding that were granted under the 1998 Stock
Option Program or the 2007 Stock Incentive Program. The outstanding stock
options as of December 31, 2009 were as follows:
Name |
|
1998 Program |
|
2007 Program |
|
Total |
Dr. Felix Zandman |
|
237,000 |
|
— |
|
237,000 |
Dr. Gerald Paul |
|
158,000 |
|
— |
|
158,000 |
Dr. Lior Yahalomi |
|
— |
|
75,000 |
|
75,000 |
Marc Zandman |
|
37,000 |
|
— |
|
37,000 |
Ziv Shoshani |
|
37,000 |
|
— |
|
37,000 |
Pursuant to the 1998
Stock Option Program and the 2007 Stock Incentive Program, upon termination by
retirement, death, or disability, an optionee has up to 12 months to exercise
any vested options (limited by the expiration date of the respective options).
Upon voluntary termination, the optionee has up to 60 days to exercise any
vested options. However, Vishay has, in the past, modified these terms as part
of negotiated termination agreements.
Based on the year-end
2009 closing price of $8.35 for Vishay’s common stock on the NYSE, none of the
options currently held by our named executive officers were in the
money.
Impact on Restricted Stock Units
Certain executive
officers received grants of restricted stock units. In the event of termination,
all unvested restricted stock units are forfeited. At December 31, 2009, Drs.
Zandman and Dr. Paul had 56,000 and 37,334 unvested restricted stock units,
respectively, and Messrs. Marc Zandman and Shoshani each had 6,668 unvested
restricted stock units.
Additional RSUs were
granted March 18, 2010 as described under “2010 Changes to Employment
Agreements” below.
Impact on Phantom Stock Units
Certain executive
officers receive an annual grant of 5,000 phantom stock units pursuant to their
respective employment agreements. Upon termination of employment, each executive
will receive one share of Vishay common stock for each phantom stock unit
held.
The table below shows
the total phantom stock units held by certain executive officers and the value
of the underlying common stock at December 31, 2009:
|
|
Phantom |
|
|
|
Name |
|
Stock Units |
|
Value |
Dr. Felix Zandman |
|
30,000 |
|
$ |
250,500 |
Dr. Gerald Paul |
|
30,000 |
|
$ |
250,500 |
Marc Zandman |
|
30,000 |
|
$ |
250,500 |
Ziv Shoshani |
|
30,000 |
|
$ |
250,500 |
The table above
excludes the 2010 annual grant to certain executive officers of 5,000 phantom
stock units.
42
Additional Information on Equity Compensation
Plans
The following table
provides certain information concerning our equity compensation plans as of
December 31, 2009.
|
|
|
|
|
|
|
Number of shares of |
|
|
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
remaining available |
|
|
Number of Shares of |
|
|
|
|
for future issuance |
|
|
Common Stock to be |
|
|
|
|
under equity |
|
|
issued upon exercise |
|
Weighted-average |
|
compensation plans |
|
|
of outstanding |
|
exercise price of |
|
(excluding shares |
|
|
options, warrants and |
|
outstanding options, |
|
reflected in the first |
|
|
rights |
|
warrants and
rights |
|
column) |
Equity compensation plans approved by
stockholders (1) |
|
|
|
|
|
|
|
1998 Stock Option
Program |
|
1,148,000 |
|
$ |
22.35 |
|
— |
General Semiconductor Stock Option Program |
|
1,499,000 |
|
$ |
18.32 |
|
— |
|
2007 Stock Incentive Program (2) |
|
|
|
|
|
|
|
Stock options |
|
81,000 |
|
$ |
12.70 |
|
(2) |
Restricted Stock Units |
|
155,000 |
|
|
n/a |
|
(2) |
Total 2007 Stock Incentive Program |
|
236,000 |
|
|
|
|
2,595,000 |
|
Senior Executive Phantom Stock Plan (3) |
|
120,000 |
|
|
n/a |
|
145,000 |
Total approved by
stockholders |
|
3,003,000 |
|
|
|
|
2,740,000 |
|
Equity compensation plans not approved
by stockholders |
|
— |
|
|
|
|
— |
Total equity compensation
plans |
|
3,003,000 |
|
|
|
|
2,740,000 |
|
|
|
|
|
|
|
|
____________________
(1) |
|
Additional information about these plans is presented in Note 12 to
the Company's consolidated financial statements, which are included in the
Company's Annual Report on Form 10-K for the year ended December 31,
2009. |
|
(2) |
|
The
2007 Stock Incentive Program provides for the grant of stock options,
restricted stock, unrestricted stock, and restricted stock units.
Therefore the shares available for future issuance are presented only in
total for the program. |
|
(3) |
|
The
Senior Executive Phantom Stock Plan provides for the granting of phantom
stock units to individuals whose employment arrangements with the Company
provide for such grants. Each phantom stock unit entitles the recipient to
receive a share of Vishay common stock at the individual's termination of
employment or any other future date specified in the employment agreement.
Because these awards have no exercise price, there is no calculation of
the weighted average exercise price. |
43
2010 Changes to Employment Agreements
On March 18, 2010,
the Compensation Committee of the Board of Directors approved certain changes in
the employment arrangements for Dr. Paul, and the Board of Directors approved
certain changes in the employment arrangements of Dr. Zandman, Marc Zandman, and
Dr. Yahalomi, upon the recommendation of the Compensation Committee. These
arrangements (other than changes in base salaries) are expected to be included
in amendments to the employment agreements of these executive officers.
No change was made to
the executive compensation arrangements of Ziv Shoshani, who is expected to
terminate his employment with the Company and become the Chief Executive Officer
of Vishay Precision Group, Inc. following the contemplated spin-off from the
Company. See “The Spin-Off of Vishay Precision Group—Arrangements with Expected
Vishay Precision Group Directors and Officers” below for information concerning
Mr. Shoshani’s compensation arrangements with Vishay Precision Group following
consummation of the spin-off.
Base Salaries
The base salaries for
2010 are set forth below.
Name |
Positions Held |
2010 Base Salary |
Dr.
Felix Zandman |
Executive Chairman of
the Board, Chief Technical |
$975,000(a) |
|
and Business
Development Officer |
|
|
|
|
Dr.
Gerald Paul |
President and Chief
Executive Officer |
€752,776 |
|
|
(approximately |
|
|
$1,104,000)(a)(b) |
Marc
Zandman |
Vice-Chairman of the
Board, Chief Administration |
NIS
1,866,750 |
|
Officer, and President
- Vishay Israel Ltd. |
(approximately |
|
|
$475,000)(c) |
Dr.
Lior Yahalomi |
Executive Vice
President and Chief Financial Officer |
$417,000 |
|
|
|
Ziv
Shoshani |
Executive Vice
President, Vishay Precision Group |
NIS
1,201,329 |
|
|
(approximately |
|
|
$305,000)(a)(c)(d) |
(a) |
|
No change
versus prior year.
|
|
(b) |
|
Salary will be
paid in Euro.
|
|
(c) |
|
Salary will be
paid in Israeli shekels.
|
|
(d) |
|
Until the
proposed spin-off occurs. Upon successful completion of the spin-off, Mr.
Shoshani’s base salary will be
$420,000.
|
Annual Incentive Cash
Programs
The employment
agreements of Marc Zandman and Dr. Yahalomi will be amended to provide for
changes to their annual cash incentive bonus.
Marc Zandman’s target
bonus will be 50% of base salary with no minimum and a maximum bonus of 200% of
base salary. Performance goals for purposes of the annual bonus award will be
recommended by the Chief Executive Officer and approved by the Compensation
Committee.
Dr. Yahalomi’s target
bonus will be 50% of base salary with no minimum and a maximum bonus of 200% of
base salary. Performance goals for purposes of the annual bonus award will be
recommended by the Chief Executive Officer and approved by the Compensation
Committee.
44
Long-term Equity Incentives
The employment
agreements of the named executive officers will be amended to provide for annual
grants of equity-based compensation in the form of restricted stock units. Of
the total equity-based compensation grant, 25% will be in the form of
time-vested restricted stock units (“RSUs”) that carry only a service condition.
The remaining 75% of the grant will be in the form of performance-vested
restricted stock units, or performance stock units (“PSUs”). The PSUs will vest
if certain defined performance criteria established by the Registrant’s
Compensation Committee are realized. The grants will be made pursuant to the
Vishay Intertechnology 2007 Stock Incentive Program. They will be based upon a
percentage of base salary for the then current year as follows:
Name |
|
LTI Value |
Dr. Felix Zandman |
|
160% of base salary |
Dr. Gerald Paul |
|
150% of base salary |
Marc Zandman |
|
100% of base salary |
Dr. Lior Yahalomi |
|
100% of base salary |
The number of units
granted annually to each executive will be determined by multiplying the
executive's base salary for the applicable year by the respective percentage set
forth above and dividing by the closing price of the Registrant’s common stock
on the New York Stock Exchange on the last trading day preceding January 1 of
the applicable year. For the purpose of the 2010 grants only, however, the total
number of units was calculated based on a market price in proximity to the date
of approval of the new long-term equity incentives. The RSUs and PSUs will
time-vest on January 1 of the third year following grant, with the performance
vesting of the PSUs to occur on the date that the Compensation Committee
certifies that the performance criteria have been satisfied.
The grants for 2010
under these new equity compensation arrangements, which will time-vest on
January 1, 2013, are as follows:
|
|
|
|
|
|
Total Units |
Name |
|
RSUs
Granted |
|
PSUs
Granted |
|
Granted |
Dr. Felix Zandman |
|
37,000 |
|
111,000 |
|
148,000 |
Dr. Gerald Paul |
|
39,000 |
|
118,000 |
|
157,000 |
Marc Zandman |
|
11,000 |
|
34,000 |
|
45,000 |
Dr. Lior Yahalomi |
|
10,000 |
|
30,000 |
|
40,000 |
Other
Dr. Paul also
received a special one-time equity-based compensation grant representing
approximately $500,000 in value. The one-time equity-based compensation grant
was in the form of 46,500 time-vested restricted stock units, which will vest on
January 1, 2013. The grant is being made in consideration of Dr. Paul’s having
led the company through the recent recession successfully while building
cash.
The Spin-Off of Vishay Precision
Group
As previously
announced, the Company intends to spin-off its precision measurement and foil
resistors businesses into an independent, publicly-traded company to be named
Vishay Precision Group, Inc.
Special Transaction
Bonuses
The Board of
Directors approved special transaction bonuses related to the Vishay Precision
Group spin-off. Upon the successful completion of the spin-off, Dr. Paul, Dr.
Yahalomi, and Marc Zandman will each receive a $500,000 cash bonus.
See “Arrangements
with Expected Vishay Precision Group Directors and Officers” below for
incentives to Mr. Shoshani for the successful completion of the Vishay Precision
Group spin-off.
45
Arrangements with Expected Vishay Precision
Group Directors and Officers
The Registrant’s
Strategic Affairs and Compensation Committees recommended to the Registrant’s
Board of Directors the terms of the compensation of the executive officers and
chairman of the board of Vishay Precision Group, to become effective upon
consummation of the spin-off. On March 18, 2010, the Registrant’s Board of
Directors approved these compensation arrangements. These include Ziv Shoshani
and Marc Zandman, both of whom are currently executive officers of the
Company.
Ziv Shoshani
Upon consummation of
the spin-off, Mr. Shoshani will become the President and Chief Executive Officer
of Vishay Precision Group, Inc. It is anticipated that Mr. Shoshani will enter
into a three-year employment agreement with Vishay Precision Group following the
spin-off. The following is a summary of the terms of Mr. Shoshani’s employment
arrangements with Vishay Precision Group, as well as certain other compensation
that he will be eligible to receive in connection with the
spin-off.
Cash compensation. Mr. Shoshani will receive a base salary of
$420,000, payable in Israeli currency based on the average exchange rate during
the preceding calendar year. In addition, he will be eligible for an annual cash
performance bonus. His target bonus will be 75% of base salary with no minimum
and a maximum bonus of 200% of base salary. Performance goals for purposes of
the annual bonus award will be established each year by the compensation
committee of Vishay Precision Group.
Equity compensation. Mr. Shoshani will be entitled to receive an
annual long-term equity incentive award with a target value equal to 100% of
base salary. The form of the annual equity award will be as determined by the
compensation committee of Vishay Precision Group. Mr. Shoshani will also receive
a founder’s equity grant having a total value of $800,000. The grant will take
the form of Vishay Precision Group restricted stock units (RSUs), all of which
will vest three years from the distribution date. The RSUs will also vest on a
change of control and in certain other circumstances to be determined by the
compensation committee of Vishay Precision Group. These equity grants will be
made pursuant to the Vishay Precision Group 2010 Stock Incentive Program, which
is expected to be adopted prior to the spin-off.
Special bonuses. Mr. Shoshani will receive from Vishay
Precision Group a cash sign-on bonus of $400,000 upon consummation of the
spin-off. Mr. Shoshani will be obligated to repay this bonus if he terminates
his employment with Vishay Precision Group during the initial three-year term of
his employment contract, other than termination for good reason, death or
disability. Mr. Shoshani will also receive a one-time cash bonus from the
Company in the amount of $600,000 upon the successful completion of the
spin-off.
Severance. If Mr. Shoshani’s employment is terminated
without cause or if he terminates his employment with Vishay Precision Group for
good reason, he will be entitled to receive cash severance in an amount equal to
two years’ base salary plus a prorated amount of this target bonus for the year
of termination. Mr. Shoshani will also be entitled to a customary continuation
of benefits. Mr. Shoshani will not be entitled to a tax gross up in respect of
any parachute payment tax imposed on his severance benefits, and, if a tax of
this nature would otherwise be imposed, the severance payments will be cut back
to the extent necessary to avoid this tax.
Other. Mr. Shoshani will be entitled to such other
benefits, including retirement benefits, as may be approved by the compensation
committee of Vishay Precision Group following the spin-off. He will also be
subject to a customary non-competition agreement for a period of two years
following termination of his employment with Vishay Precision Group. “Cause,”
“good reason” and “change of control” will be as defined in Mr. Shoshani’s
employment agreement.
46
Marc Zandman
Marc Zandman is
expected to be the non-executive Chairman of the Board of Directors of Vishay
Precision Group. Mr. Marc Zandman will receive an annual $75,000 retainer for
his service on the Vishay Precision Group Board of Directors. Upon successful
completion of the spin-off, Mr. Marc Zandman will also receive a founder’s
equity grant having a total value of $75,000. The grant will take the form of
Vishay Precision Group restricted stock units (RSUs), which will vest pro rata
over three years. These equity grants will be made pursuant to the Vishay
Precision Group 2010 Stock Incentive Program.
Other Executive Officers
The Strategic Affairs
and Compensation Committees also recommended to the Registrant’s Board of
Directors the terms of employment arrangements with other persons expected to
assume executive officer roles of Vishay Precision Group upon the completion of
the Vishay Precision Group spin-off. On March 18, 2010, the Company’s Board of
Directors approved these compensation arrangements. These employees are not
presently executive officers of the Company. The terms of these arrangements
will be disclosed in the Vishay Precision Group Form 10 registration statement
required to be filed in connection with the spin-off.
Director Compensation
On March 18, 2010,
the Board of Directors determined to award to each of the non-management
directors an annual grant of 10,000 restricted stock units (“RSUs”). The RSUs
will vest three years from the date of grant, with pro rata vesting upon earlier
cessation of service. These grants will be made pursuant to the Vishay
Intertechnology 2007 Stock Incentive Program. Mr. Maier was awarded 7,500 RSUs
upon being elected to the Board. These RSUs will vest on March 18, 2013, with
pro rata vesting upon earlier cessation of service.
47
CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS
Vishay maintains
employment agreements with our Executive Chairman, Chief Executive Officer, and
each of our other executive officers. See “Executive Compensation”
above.
Yitzhak Shoshani is
the brother of director Ruta Zandman and the uncle of director and executive
officer Ziv Shoshani. Mr. Yitzhak Shoshani is Vice President and General Manager
of, and owns 33.3% of, Ecomal Israel, a non-exclusive distributor of our
products mainly in the Israeli market. Mr. Yitzhak Shoshani earned $127,468 in
salary, and $300,000 in the form of dividend due to the performance of Ecomal
Israel for 2009.
Dubi Zandman is a
cousin of Executive Chairman Dr. Felix Zandman and a Vice President of the
Vishay Measurements Group. For 2009, Mr. Dubi Zandman received salary and bonus
of $187,496.
Steven C. Klausner is
the son-in-law of Dr. Felix Zandman and Ruta Zandman and the brother-in-law of
Vice Chairman Marc Zandman. Mr. Klausner is a Vice President and Treasurer of
Vishay. For 2009, Mr. Klausner received salary, bonus, and benefits totaling
$177,619.
Roy Shoshani is the
brother of Ziv Shoshani and the nephew of Ruta Zandman and Dr. Felix Zandman. He
is currently Senior Director Division at Siliconix. For 2009, Mr. Roy Shoshani
received salary and benefits totaling $269,242. His benefits include $61,283 for
a housing allowance (which is customary for any Vishay employees on
international assignments).
Eli Goddard is the
son-in-law of Dr. Felix Zandman and Ruta Zandman and the brother-in-law of Marc
Zandman and has performed legal services for Vishay Israel Limited. For 2009,
Mr. Goddard received a consulting fee of $77,194.
Alon Shagir is the
brother-in-law of Marc Zandman. Mr. Shagir is employed by Vishay Israel Limited
as a process engineer. For 2009, Mr. Shagir received salary and benefits
totaling $35,863.
Ron Shoshani is a
nephew of Ruta Zandman and Dr. Felix Zandman and a cousin of Ziv Shoshani. Mr.
Ron Shoshani is employed as a sales engineer by Vishay Israel Limited. For 2009,
Mr. Ron Shoshani received salary and benefits totaling approximately
$60,563.
Shay Shoshani is a
nephew of Ruta Zandman and Dr. Felix Zandman and a cousin of Ziv Shoshani. Mr.
Shay Shoshani is employed as a bookkeeper by Ecomal Israel. For 2009, Mr. Shay
Shoshani received salary and benefits totaling approximately
$56,326.
Our Board has adopted
a written Related Party Transaction Policy that governs the review, approval, or
ratification of related party transactions. The Nominating and Corporate
Governance Committee has the responsibility to administer the policy. All
related party transactions, including employment relationships and charitable
contributions, must be approved or ratified by the Committee. Members of the
Committee may not participate in any review, consideration, or approval of any
transaction involving such member, any family member of such member, or any
entity with which such member is affiliated. A copy of the Related Party
Transaction Policy is available to stockholders on our website and in print upon
request.
Our Related Party
Transaction Policy requires that all new employment relationships with a family
member of a director or executive officer be approved by the Committee. The
Committee also must undertake an annual review of on-going employment
relationships of family members of any director or executive
officer.
48
OTHER MATTERS
This proxy statement
includes all of the business that the Board of Directors intends to present at
the annual meeting. The Board of Directors is not aware of any other matters
proposed to be presented at the meeting. If any other matter or matters are
properly brought before the annual meeting or any adjournment thereof, it is the
intention of the person named in the accompanying form of proxy to vote the
proxy on such matters in accordance with their judgment.
AVAILABILITY OF ANNUAL REPORT AND FORM 10-K TO
STOCKHOLDERS
Our Annual Report to
Stockholders for the year ended December 31, 2009 accompanies this proxy
statement. Vishay will provide to any stockholder, upon written request and
without charge, a copy of our most recent Annual Report on Form 10-K, including
the financial statements, as filed with the Securities and Exchange Commission.
All requests for such reports should be directed to Investor Relations, Vishay
Intertechnology, Inc., 63 Lancaster Avenue, Malvern, PA 19355, telephone number
(610) 644-1300.
STOCKHOLDER PROPOSALS FOR 2011 ANNUAL
MEETING
To be eligible for
inclusion in our proxy materials for the 2011 annual meeting, a stockholder
proposal must be received by our Corporate Secretary by the close of business on
December 28, 2010.
By order of the Board of Directors, |
|
|
Peter G. Henrici |
Corporate
Secretary |
April 27,
2010
49
|
VISHAY INTERTECHNOLOGY,
INC. 59 MAIDEN LANE NEW YORK, NY
10038
|
VOTE BY
INTERNET - www.proxyvote.com |
Use the Internet to transmit your voting instructions and for
electronic delivery of information up until 11:59 P.M. Eastern Time the
day before the cut-off date or meeting date. Have your proxy card in hand
when you access the web site and follow the instructions to obtain your
records and to create an electronic voting instruction form.
|
|
Electronic Delivery of Future
PROXY MATERIALS |
If you would like to reduce the costs incurred by our company in
mailing proxy materials, you can consent to receiving all future proxy
statements, proxy cards and annual reports electronically via e-mail or
the Internet. To sign up for electronic delivery, please follow the
instructions above to vote using the Internet and, when prompted, indicate
that you agree to receive or access proxy materials electronically in
future years.
|
|
VOTE BY
PHONE - 1-800-690-6903 |
Use any touch-tone telephone to transmit your voting instructions up
until 11:59 P.M. Eastern Time the day before the cut-off date or meeting
date. Have your proxy card in hand when you call and then follow the
instructions.
|
|
VOTE BY
MAIL |
Mark, sign and date your proxy card and return it in the postage-paid
envelope we have provided or return it to Vote Processing, c/o Broadridge,
51 Mercedes Way, Edgewood, NY 11717.
|
TO VOTE, MARK BLOCKS BELOW IN
BLUE OR BLACK INK AS FOLLOWS: |
|
|
|
|
|
|
KEEP THIS PORTION FOR YOUR RECORDS |
|
DETACH AND RETURN THIS PORTION
ONLY |
THIS PROXY CARD IS VALID ONLY
WHEN SIGNED AND DATED. |
|
|
For
All |
Withhold
All |
For
All Except |
|
|
|
|
The Board of
Directors recommends that you vote FOR the following: |
|
|
|
|
|
1. |
Election of
Directors Nominees: |
|
0 |
0 |
0 |
|
|
|
|
|
|
|
|
01 Dr. Felix
Zandman 02 Dr. Gerald
Paul 03 Frank
Maier
|
To withhold authority to vote for any
individual nominee(s), mark “For All Except” and write the number(s) of
the nominee(s) on the line below. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Board of Directors
recommends you vote FOR the following proposal(s): |
|
For |
Against |
Abstain |
|
|
|
|
|
|
|
|
2.
|
To ratify the appointment of Ernst & Young
LLP as Vishay's independent registered public accounting firm for the year
ending December 31, 2010. |
|
0 |
0 |
0 |
|
|
|
|
|
|
|
The Board of Directors
recommends you vote AGAINST the following proposal(s): |
|
For |
Against |
Abstain |
|
|
|
|
|
|
|
3. |
Stockholder Proposal |
|
0 |
0 |
0 |
|
NOTE: Such other
business as may properly come before the meeting or any adjournment
thereof. |
|
|
|
For address change/comments, mark here. (see reverse for
instructions) |
|
|
0 |
|
|
Yes |
No |
|
|
Please
indicate if you plan to attend this meeting |
0 |
0 |
|
|
|
|
|
|
|
Please sign exactly as your
name(s) appear(s) hereon. When signing as attorney, executor,
administrator, or other fiduciary, please give full title as such. Joint
owners should each sign personally. All holders must sign. If a
corporation or partnership, please sign in full corporate or partnership
name, by authorized officer.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature [PLEASE SIGN WITHIN BOX] |
Date |
|
|
Signature (Joint Owners) |
Date |
|
Important Notice Regarding the Availability of Proxy
Materials for the Annual Meeting of
Stockholders to be held June 16,
2010.
The following materials, also included with this
Notice, are available for view on the Internet:
Proxy Statement for the 2010 Annual Meeting of
Stockholders
2009 Annual Report to
Stockholders
To view these materials, visit http://ir.vishay.com
Important Notice Regarding the
Availability of Proxy Materials for the Annual Meeting: The Annual
Report, Notice & Proxy Statement is/are available at
www.proxyvote.com.
|
VISHAY INTERTECHNOLOGY, INC.
2010 Annual Meeting of
Stockholders
The undersigned hereby appoints Dr. Felix
Zandman, Dr. Gerald Paul, and Dr. Lior Yahalomi, and each of them acting
individually, with full power of substitution, to vote all shares of common
stock and Class B common stock of Vishay Intertechnology, Inc. which the
undersigned is entitled to vote at the Annual Meeting of Stockholders of Vishay
Intertechnology, Inc. to be held at the Rittenhouse Hotel Ballroom, 2nd Floor at
210 West Rittenhouse Square, Philadelphia, PA 19103, at 10:30 a.m., local time,
on Wednesday, June 16, 2010, and at any adjournment thereof, hereby ratifying
all that said proxies or their substitutes may do by virtue hereof, and the
undersigned authorizes and instructs said proxies to vote as
follows:
PLEASE DATE, SIGN AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED
ENVELOPE.
(If you noted any Address Changes and/or Comments above, please mark
corresponding box on the reverse side.)
(Continued and to be dated and signed on the other
side.)